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N-linked glycosylation is a common protein post-translational modification
where glycans are attached to asparagine residues located on a consensus se-
quence. Structure of these glycans varies widely among species, which is of
particular importance given the role that glycans play on protein folding, func-
tionality and recognition. Notably, glycans are often necessary to maintain sta-
bility and efficacy of therapeutic proteins in the human body.
Production of therapeutic glycoproteins in Escherichia coli has the potential
to become a flexible and relatively cheap alternative to current production sys-
tems, even though E. coli has no native protein glycosylation machinery. Re-
cently, the glycosylation machinery from Campylobacter jejuni, a gram negative
bacterium, was transferred to E. coli, making protein glycosylation possible for
the first time in this host. Unfortunately glycans synthesized by C. jejuni, and
bacteria in general, are not appropriate for use in human therapeutics, hence
engineering the synthesis of human-like glycans in E. coli becomes necessary.
This study is focused on recombinant expression and engineering of eukary-
otic glycosyltransferases to enable E. coli to synthesize eukaryotic-like glycans
suitable for in vivo production of therapeutic glycoproteins.
Initially, we expressed glycosyltransferases from Saccharomyces cerevisiae
(Alg13, Alg14, Alg1 and Alg2) for the synthesis of a core glycan structure (tri-
mannose core) common to many human glycans. Later, the work was ori-
ented towards the extension of this trimannose core for production of authentic
human-like glycans and improvement of the current system using directed evo-
lution of glycosyltransferases. In the future, we expect to be able to produce
glycosylated proteins in vivo, displaying fully sialylated human-like glycans.
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CHAPTER 1
INTRODUCTION
The glycome, defined as the totality of carbohydrates in an organism, is con-
sidered as “one of the most complex entities in nature” [171] even surpassing
the complexity of the genome and the proteome. The role of this glycome in
relation to the living organisms is studied by glycobiology, a relatively recent
field of biology that has been gaining importance due to its relation to other
major fields such as immunology, biochemistry and bioengineering. The term
“glycobiology” was used for the first time by biochemist Raymond Dwek at the
University of Oxford, UK in 1988 [20]. The purpose of this term was to em-
phasize the role of carbohydrates and glycans in biological systems, as opposed
to the study and analysis of these molecules as isolated entities unrelated to
their biological activity [20]. The late arrival of glycobiology may be mainly at-
tributable to the fact that the actual importance of glycans in processes like cell
signaling, cell differentiation, immunological recognition and protein stability,
has only been recognized recently [131]. Moreover, it was not uncommon to
think about glycans and polysaccharides as just agents decorating cell surfaces
and protecting them from proteolysis [20].
In addition to the glycome complexity, carbohydrate analysis and glycan
analysis in general have always been challenging tasks [3, 24, 95, 131]. Among
several reasons, the high variety of glycans, their complicated structures, and
the similarity in their subunit components (monosaccharides) are the features
more often cited as responsible for this difficulty [3, 131]. It has been even stated
that technical difficulties related to glycobiology are often so high that it could
be the reason why it is difficult for some scientists to get into the field [20]. De-
spite these difficulties that can be associated to any emerging field in science,
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glycobiology has been constantly gaining momentum. We are right now at a
point that our collective knowledge, though still very limited, has already per-
mitted us to engineer biological systems around the synthesis of ad-hoc glycans.
For example, cell surface display of glycans and protein glycosylation have been
customized, taking advantage of current techniques in protein and metabolic
engineering [21, 51, 60, 64, 78, 90, 141].
Based on this advances and given their importance in nature, in this work
we focused mainly on glycans and its engineering on E. coli cells. Our goal was
to achieve in vivo synthesis of eukaryotic-like and human-like glycans in this
bacterial cells, keeping in main as a long term goal the use these engineered
glycans as precursors for in vivo synthesis of genuine human glycoproteins in E.
coli.
1.1 Glycans
Glycans are complex molecules made of monosaccharides. As shown in fig-
ure 1.1a, monosaccharides have several hydroxide groups available for reaction
and polymerization. Because of this feature, glycans can be as simple as disac-
cahrides or as complex as highly branched molecules comprising more than 10
single units (figure 1.1b).
Given these characteristics, glycans constitute the largest class of biological
macromolecules [169]. Indeed, it has been calculated that the potential variabil-
ity of glycans surpasses that of nucleic acids and peptides by several orders of
magnitude [93]. Interestingly, while the number of common monosaccharides
(approximately 12) is less than the number of common amino acids (20), the
fact that glycans can happen as branched molecules and each subunit have 3
or more functional groups available for polymerization, accounts for the higher
2
a)
b)
Bac
C. jejuni Human
biantennary
Human
high mannose
Human
core 2
GlcNAc GalNAc
O
OH
HO
HO
CH2
OH
NH
CO
CH3
O
OHHO
HO CH2
OH
NH
CO
CH3
O
OH
HO
HO
CH2
OH
OH
D-Glucose D-Mannose
O
OHHO
HO
CH2
OH
OH
O
OH
HO
CH3
NH
CO
CH3
HN
CO
CH3
Bacillosamine
L-Fucose
O
OH
HO
CH3
OH
OH
Bac
O
OHHO
HO CH2
OH
OH
D-Galactose
NHAc
HO
COO
OH
Sialic Acid
O OH
OHHO
Figure 1.1: Glycans in nature. (a) Some monosaccharides commonly found as subunits
in glycans. (b) examples of glycan variety in nature [108].
variability when compared with peptides and nucleic acids, which are restricted
to a linear configuration (figure 1.2).
Thanks to this variability, glycans can store massive amounts of information.
However, because of this variability, analysis and identification of glycans is still
difficult mainly because monosaccharides are very similar among them [131].
For instance, glucose, mannose and galactose are just positional isomers where
the only difference is the relative position of their hydroxide groups. Because of
this factor, development of enhanced analytical methods applicable to carbohy-
drates is advancing constantly. Unfortunately many of the new techniques are
still in their infancy and a fully standardized methodology for analysis is not
available yet.
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Figure 1.2: Glycan variability. Schematics comparing the potential size of the glycome
in comparison with the proteome, the transcriptome and the genome (the
diagram is not drawn to scale). Adapted from [62].
1.1.1 Glycan analysis
With glycobiology gaining more attention, analysis methods aimed at carbohy-
drates have been going through notorious improvement. Some traditional tech-
niques, such as radiolabeling, are slowly being displaced by more convenient
approaches like HPLC and capillary chromatography, while other classic tech-
niques like fluorophore assisted carbohydrate electrophoresis (FACE), are being
modified for enhanced results. Since any glycobiology related project is com-
pletely dependent on successful application of these techniques, a brief review
of most prevalent methods for carbohydrate analysis is presented as follows.
Radiolabeling
Radiolabeling of glycan precursors is a method that has been applied to lipid
linked oligosaccharide (LLO) analysis since nearly 30 years ago [140, 156].
In general, [2-3H]mannose is fed directly to cells which can metabolize it
into [2-3H]mannose-6-P, followed by [2-3H]mannose-1-P, and finally to GDP-
[2-3H]mannose [97]. This last compound, GDP-mannose or its radiolabeled
version GDP-[2-3H]mannose, is the activated donor for several glycosyltrans-
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ferases; hence [2-3H]mannose can be incorporated into a variety of glycans and
exploited for further analysis [140].
Alternatively, other radiolabeled carbohydrates like [1-3H]N-acetylglucosamine
and [1-3H]galactose [97, 138] can be used to target more specific glycans or
as additional controls. In particular, [2-3H]mannose is preferred for eukary-
otic LLOs analysis, given the presence of multiple mannose subunits in most of
those molecules, which results on stronger signals and hence higher sensitivity
[97].
In general, the labeled sugars are added directly to cell culture during ap-
proximately 5min. Radioactive medium is then removed and lipids are ex-
tracted using chloroform and methanol. Thin layer chromatography (TLC) is
commonly used for analysis of radioactive LLOs. Alternatively, glycans can be
released from LLOs an then analyzed using liquid chromatography or FACE
[140]. The main drawback of this approach resides precisely in the final analy-
sis step; where methods like chromatography or electrophoresis can fail when
trying to separate molecules that are very similar. Also, since this method can
only provide limited information about glycan structure and composition, com-
plementary analyses are required.
Fluorophore assisted carbohydrate electrophoresis (FACE)
Electrophoresis of glycans depend mainly on two characteristics: the elec-
trophoretic mobility of glycans and the capacity of detecting and imaging these
glycans directly in a gel. Many monosaccharides and glycans are not charged
(they will not migrate during electrophoresis) or are just lightly charged [125],
which together with their lack of chromophoric or fluorophoric groups, make
them relatively hard to detect and not suitable for electrophoresis analysis [158].
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These inconveniences have been addressed by conjugation of charged fluo-
rophores which can tackle both the electrophoretic mobility and the detection
problem, enabling glycans and carbohydrates for electrophoresis analysis [158].
In general, aromatic primary amines have been the fluorophores of choice,
being gradually replaced by polysulfonic acid derivatives such as 8-amino-
naphthalene-1,3,6-trisulfonate (ANTS) and 7-amino-1,3-naphthalenedisulfonic
acid (ANDS) [56].
FACE analysis presents important advantages including the low cost of re-
quired reagents and equipment, relatively simple experimental set-up, and the
fact that radioactive precursors are not required [55]. On the other hand, ex-
cept for the addition of radioactive carbohydrates, the experimental setup for
FACE is completely analogous to the setup previously described for radiolabel-
ing, where cells are grown for a determined period of time and LLOs are then
extracted for analysis. The main difference is found after glycans are released
from LLOs by acid hydrolysis. When applying FACE, glycans are derivatized
using the fluorophore of choice, by reductive amination, and then samples are
loaded into a polyacrylamide gel for electrophoresis. Glycans can then be de-
tected by fluorescence using a UV transilluminator [56, 97, 158]. Unfortunately,
as is the case with radiolabeling, information about glycan structure and compo-
sition obtained using FACE is relatively limited and complementary approaches
are necessary depending on the case.
Metabolic labeling of glycans with bioorthogonal modified carbohydrates
Recently, some modified carbohydrates have emerged as bioorthogonal com-
pounds able to get incorporated into glycan structures without interfering with
their metabolic activity and facilitating glycan detection and analysis by mean
6
of reactions like azide-alkyne (click chemistry) or azide-phosphine (Staudinger
reaction). This method dates from 1992, when Reutter and coworkers modified
N-acetylmannosamine replacing the acetyl group by an acyl chain homologue.
After incorporation and metabolization of the modified carbohydrate, the acyl
chain permitted detection and analysis of modified N-acetyl neuraminic acid,
directly derived from modified N-acetylmannosamine inside cells [83, 94]. Fur-
ther modifications to this technique include the use of ketones, thiol and azide
groups in replacement of the acyl group, making the technique more flexible
and extending its potential applications [94].
In general, azide sugars have been preferred over other modified carbohy-
drates based on azides high intrinsic reactivity, selectivity, stability in water,
and unreactivity respect to most biological compounds [17]. Also, the azide
moiety is small, making it ideal for carbohydrate modification [17, 95]. Its de-
tection relies mainly on two approaches: click chemistry and the Staudinger
reaction. Azide-alkyne cycloaddition is a typical click chemistry reaction, it is
copper-catalyzed and has a rapid rate of reaction. However, its major drawback
is copper toxicity and hence limited application on in vivo labeling [17]. On the
other hand, the main application for Staudinger ligation is precisely in in vivo
labeling. This reaction is particularly useful when a phosphine is attached to
the azide group, being the advantage based on the fact that phosphine can be
conjugated to a variety of tags such as biotin, FLAG, myc and His6 facilitating
considerably its detection [3, 94]. Besides that, the main limitation of these meth-
ods is related to the availability of modified sugars. Azide sugars can only be
obtained from N-acetylate carbohydrates like N-acetylglucosamine (GlcNAc) or
N-acetylgalactosamine (GalNAc) [95]. Because of this limitation, the method is
restricted only to certain glycan structures.
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Successful applications of bioorthogonal modified carbohydrates include
labeling of fucosylated glycans in mammals, protein glycosylation studies in
bacteria, tagging of O-GlcNAc modified proteins, and glycan analysis in yeast
[22, 39, 86, 157, 190].
Lectin analysis and microarrays
Antibodies have been extensively used for protein detection and cell labeling
mainly thanks to their relatively good availability, high specificity, and ease of
use. In general, new antibodies can be obtained by inoculating a suitable mam-
mal with the protein (antigen) of interest, then the animal’s immune system
may generate “new” antibodies against this protein and then these antibodies
(IgGs in particular) can be further purified from the animal’s serum for further
use. Unfortunately in the case of glycans this protocol is no as useful as it is
with proteins. The main challenge in this case is related to the fact that, in gen-
eral, the immunogenicity of carbohydrates is relatively low [66], so antibodies
against glycans are difficult to obtain using traditional methods.
Even though there are available antibodies against some glycans, lectins
are more commonly used for glycan affinity-based detection. However, it is
important to keep in mind that, compared to antibodies, lectins usually have
relatively low affinity for their carbohydrate epitope and many times rely on
multivalency for appropriate binding [95]. Despite these disadvantages, lectins
have proven to be widely useful and have some of the advantages attributed
to antibodies. For example, lectins can be used for cell surface labeling in vivo,
detection of glycoproteins in an immunoblotting analogous way, labeling of tis-
sues and organs, and agglutination analysis of bacterial and mammalian cells
[49, 62, 68, 95, 152, 161].
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In the context of this project, concanavalin A (ConA), a lectin extracted
from Canavalia ensiformis, is of particular interest given its affinity towards
mannose and several oligosaccharides displaying terminal mannose residues
[114, 117, 136]. Because of this feature, it has been extensively used in tissue
analysis. However, its importance for this project resides on its high affinity
towards the “trimannose core”, an eukaryotic like glycan which synthesis was
considered as our main goal [114, 117]. This feature permitted us multiple kinds
of analysis, like surface labeling of E. coli cells and detection of glycoproteins
and glycolipids.
Recently, lectin analysis has evolved from the use of single lectins to the
arrangement of several lectins into microarrays for high throughput analy-
sis. Lectin microarray technology depends on immobilization of these proteins
over a solid substrate. Immobilization methods tested so far include: carbene
insertion, interaction between biotin and avidin, and use of amino acid side
chains like lysine [62]. Applications of this technology are quickly increasing
and include analysis of bacterial glycome and its response to metabolic alter-
ations, glycan profiling and identification, glycan-based identification of bacte-
rial pathogens, and clinical diagnostic [42, 71, 82, 91, 164].
Finally, it is worth to mention that lectin analysis provides some insight into
glycan structure, given the specificity of lectins towards certain carbohydrate
motives. Based on this factor, glycan microarrays have been applied alongside
with mass spectrometry (MS) for the analysis of protein glycosylation profiles
and glycan identification [62]. Still, the information obtained from this approach
is often not enough for a complete identification and more sophisticated tech-
niques are necessary.
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Mass spectrometry (MS)
MS comprises a good number of different methods and techniques where a sin-
gle one is probably not good enough for analyzing every single kind of glycan.
Matrix-assisted laser desorption/ionization (MALDI) is the most widely used,
given most glycans give signals under the conditions for this method even on
their native states [65].
Often, glycans occur in nature conjugated to lipids and proteins. Because
of that, when possible, it is preferred to release them before analysis to facili-
tate the interpretation of results [115]. When glycans are attached to proteins,
enzymatic releasing is preferred, being PNGase F the most popular enzyme for
this purpose [165]. On the other hand, releasing of glycans from lipids is usu-
ally achieved by acid hydrolysis followed by liquid-liquid extraction and drying
[56, 80]. It is also important to take into account that glycans are not ionized as
efficiently as other molecules like proteins, a reason why derivatization is fre-
quently used before MALDI to obtain improved results. Permethylation with a
methyl iodide is the most common approach for increasing ionization efficiency
and hence enhanced detection [65]. Permethylation is also particularly useful
for stabilization of sialylated glycans, given sialic acid is easily removed from
these molecules by hydrolysis, making its analysis more difficult [115].
Recent advances on MS/MS analysis and MSn techniques have provided
further insight into glycan structure, having now the possibility of obtaining
basic information respect to sequence, linkage, and branching based primarily
on MS analysis [134, 150]. Nevertheless, despite all the advances on MS, most
detailed analysis of glycans is still challenging. The main problem is still related
to the similarity among monosaccharide subunits. In particular, it is not possible
to discriminate structural isomers using MS, being only possible to characterize
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these monosaccharides generically as pentoses or hexoses [104], for exmaple, so
definitive identification still relies on NMR analysis.
Nuclear magnetic resonance (NMR)
As mentioned before, carbohydrate structural isomers cannot be identified us-
ing solely MS, being NMR analysis crucial for detailed glycan identification and
analysis [46]. NMR is then the ultimate tool for glycan analysis, permitting
a complete identification of both glycan structure and monosaccharide nature.
Generally, NMR spectra is analyzed by expert personal, supported on special-
ized software and glycan structure databases [96].
Usually, glycan NMR analysis requires from a few micrograms to a couple
miligrams of sample [23, 61], which, depending on the glycan source, could
represent an additional challenge given sometimes is difficult to obtain enough
amounts of sample. Still, it is generally considered that NMR is to certain point
independent of the sample size [46].
Finally, it is worth to mention that publishing good NMR data has been gain-
ing importance on the glycobiology field. Because of that, reporting tables of
chemical shifts is a widespread practice and recommended when presenting
NMR results [46].
1.2 Protein glycosylation
Glycosylation of proteins is the most common post-translational modification
in nature. It is present in all three domains of life playing a role on protein local-
ization, recognition, folding and quality control [107]. N-linked and O-linked
glycosylation are the prevalent types of protein glycosylation, being N-linked
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glycosylation the most abundant and the best understood. N-linked glycosy-
lation refers to the covalent conjugation of a glycan molecule to an asparagine
(N) residue in a protein. To be glycosylated, this asparagine residue has to be
part of a recognition sequence of amino acids: N-X-S/T (where X is any amino
acid but proline) in the case of eukaryotes [107]. In prokaryotes, the N-X-S/T se-
quon is not necessarily sufficient, like is the case for Campylobacter jejuni where
the recognition sequence is extended to D/E-Z-N-X-S/T (where Z is any amino
acid but proline) [88], being D-Q-N-A-T the optimal acceptor sequence [29] for
this organism.
Interestingly, the N-linked glycosylation process shows homologous fea-
tures in all three domains of life, for example, glycans are usually assembled
stepwise by several glycosyltransferases over a membrane embedded lipid car-
rier. The resulting structure, a lipid-linked oligosaccharide (LLO) is then flipped
to the luminal space of the endoplasmic reticulum (ER) in eukaryotes, or to the
periplasmic space in prokaryotes. In the eukaryotic case, LLOs are further mod-
ified by incorporation of additional monosaccharides to the glycan structure.
Finally, an oligosaccharyltransferase (OST) catalyzes en bloc transfer of the gly-
can to the recognition sequence in an acceptor protein [146]. Figure 1.3 shows
a schematic of the glycosylation process in C. jejuni, which is in some way a
simplified version of the eukaryotic glycosylation machinery.
The importance of protein glycosylation in nature is already well estab-
lished. However, the exact function of most glycans and their actual impact on
glycoproteins is still being investigated. From the point of view of this project,
the main interest resides on the effect that glycans have on proteins with po-
tential therapeutic applications and the possibility of producing these glycopro-
teins in E. coli.
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Figure 1.3: Schematic of C. jejuni protein glycosylation pathway. Adapted from [84].
1.2.1 Effects of glycosylation on therapeutic proteins
It has been recognized that proteins can display higher specificity and potency
than small molecule based drugs. Unfortunately, their instability presents a ma-
jor challenge for pharmaceutical applications [6], where the main issue is related
protein structure (secondary and tertiary) mainly because thermodynamic sta-
bility of the protein active conformation is often not very different from the ther-
modynamic stability of some inactive conformations and hence proteins may
easily lose activity under certain circumstances. Because of this problem, most
of the current efforts are focused on strategies for maintaining an stable active
conformation of these therapeutic proteins under physiological conditions [7].
Among several strategies available to protect these active conformations the
most commonly used are the insertion of mutations in the amino acid sequence,
use of excipients in the final formulation, protein pegylation, and protein glyco-
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sylation. Particularly, glycosylation is desired, given it has been shown to have
effects not just on stability and protein structure but also on the therapeutic effi-
cacy of these proteins. It has also being suggested that all the beneficial effects of
glycosylation are dependent on several characteristics like glycosylation degree
(site occupancy), glycan size and glycan structure [154].
Glycans can also prevent protein aggregation mainly because of their hy-
drophilic nature, increasing the solvent accessible area of the protein and hence
making glycoproteins more soluble [153]. Furthermore, it has also been found
that glycosylation confers additional resistance to extreme pH, chemical denat-
uration, and thermal denaturation [154]. On the other hand, the in vivo stability
of therapeutic proteins depends strongly on its resistance to proteolytic degra-
dation [163] which has been demonstrated to be related to proper glycosylation
[151]. It was suggested that this resistance is conferred due to the steric in-
terference provided by the glycan, blocking direct contact of the protease with
the protein backbone and preventing cleavage [15, 154]. It is also important
to mention that glycans, and in particular terminal-sialylated glycans, affect
serum half-life of proteins. One reason for this is that non-sialylated glycans
with terminal galactose (Gal) or GlcNAc residues are recognized by the asialo-
glycoprotein receptor on the surface of hepatocytes, leading to protein internal-
ization and degradation [15]. This fact makes evident that the protein glycosy-
lation problem is not just limited to glycan conjugation, but instead, it is also re-
lated to glycan structure. For example, human cells produce only Neu5Ac-type
sialic acid while other mammals produce the slightly different Neu5Gc-type,
because of that, some glycoproteins produced in non-human cells happen to be
immunogenic [126]. In a similar way, xenotransplantation of organs from pigs
is prevented because Gal residues in pig glycans are attached by an α1,3 linkage
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which also results immunogenic to humans [135].
Using bacterial glycans does not seem to be adequate either. In principle, C.
jejuni glycosylation machinery could be exploited for therapeutic glycoprotein
production in bacteria. However, the problem with this approach arises from
evidence suggesting that the immunogenicity of certain glycoproteins from this
bacterium is strongly related to the glycan moiety attached to them, making C.
jejuni glycan unsuitable for use in humans [162].
In summary, therapeutic application of glycoproteins is gaining importance
thanks to the accumulated evidence showing how glycans impact both stability
and activity of proteins in humans. Nevertheless, it is not just a matter of attach-
ing glycans to proteins, on the contrary, glycan localization and glycan structure
are also important factors to take into account, adding to the complexity of the
glycoprotein engineering problem.
1.2.2 N-linked glycans in eukaryotes
The protein glycosylation process has been, to some extent, conserved across all
three domains of live. As mentioned before, the process is centered on LLO syn-
thesis occurring at the membrane level and transferring of the whole glycan to a
receptor protein by an OST, where the main differences between the eukaryotic
and prokarytic processes are the glycan structures and the nature of the OST.
In regard to glycan structure, the investigations so far suggest that there is
considerable variety on bacterial N-linked glycans and it is suspected that this
variability is even higher for archaeal organisms. In contrast, the vast majority
of eukaryotes synthesize the same glycan precursor: Glc3-Man9-GlcNAc2 (glu-
cose: Glc, mannose: Man, N-acetylglucosamine: GlcNAc), so the actual vari-
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ability in eukaryotic glycans is a result of further modifications happening in
the late ER or the Golgi [146]. Figure 1.4 shows a sample of such variety in
human N-linked glycans.
NeuNAc Gal Man GlcNAc
Figure 1.4: Common glycans found in human glycoproteins. The highlighted residues con-
stitute the “common core” or “trimannose core” (adapted from [115]).
It is important to address how all structures in Figure 1.4 share a common
“trimannose core”. Notably, the trimannose core, as part of the Glc3-Man9-
GlcNAc2 precursor, is a conserved structure in eukaryotes which means also
that its biosynthetic pathway is virtually the same from protozoans to humans
[2, 146].
1.2.3 Engineering human-like N-linked protein glycosylation
By 2006 the therapeutic protein market was calculated on US $57 billion, con-
stituting the the most important class of new products in the biopharmaceutical
industry. Given proper glycosylation is indispensable in this field, mammalian
cell expression systems are preferred because they are better suited for synthesis
of human-compatible glycans. Among these expression systems can be listed
Chinese Hamster Ovary (CHO) cells, mouse myeloma cells, human fibrosar-
coma cells, human lymphoma, and human embryo kidney cells [45]. Never-
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theless, these platforms present several drawbacks, like the need for expensive
media, risk of viral contamination and relatively difficult genetic manipulation
[38]. Because of that alternative systems are being investigated, being examples
of these emerging systems, modified plant cells, filamentous fungi, insect cells
and yeast cells [45].
In general, non human cells require some extent of engineering before
proper glycosylation of proteins can be achieved. For instance, CHO cells can
produce glycans resembling their human counterparts to a good extent. How-
ever, incomplete synthesis of humanized glycans in these cell lines is not rare,
which implies that an important fraction of recombinant glycoproteins will not
display terminal sialic acid. This issue has been addressed mainly by overex-
pression of β1,4-galactosyltransferase and α2,3-sialyltransferase to enforce syn-
thesis of fully sialylated glycans but the results may depend on several other
factors and are not always satisfactory [180].
In the case of plant cells, removal of β1,2-xylosylation and core α1,3-
fucosylation is generally required. This engineered cells can synthesize human-
like glycans lacking both terminal sialic acid and galactose, so additional engi-
neering is still required for production of completely humanized glycoproteins
in this system [26].
The insect cell-baculovirus system is also promising for glycoprotein pro-
duction. Fully sialylated glycans can be synthesized by recombinant expres-
sion of β1,4-galactosyltransferase and α2,6-sialyltransferase. The main prob-
lem here reside in the fact that insect cells synthesize mostly monoanten-
nary glycans, an issue that can be solved by recombinant expression of N-
acetylglusaminyltransferase II. Additional challenges are the competitive pro-
duction of highly mannosylated and terminally paucimannosylated glycans
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[69].
One of the most recent advances in production of human-like glycoproteins
is based on glycoengineering of Pichia pastoris. The first requirement in this
case is eliminating the synthesis of highly mannosylated (and highly antigenic)
glycans by deletion of the OCH1 gene, which produces a Man8-GlcNAc2 struc-
ture. Recombinant expression of mannosidases permit the generation of the
trimannose core that can be further elongated by recombinant expression of
β1,2-N-acetylglucosaminyltransferase I and II, β1,4-galactosyltransferase and
α2,6-sialyltransferase. Nevertheless, some issues still to be solved are related
to undesired O-linked glycosylation and heterogeneity in glycan structure [78].
Compared to the already mentioned systems, engineering of a bacterial
based system is still on its early steps. This is mainly due to the lack of pro-
tein glycosylation machinery in the majority of bacteria, limiting the availabil-
ity of native pathways for further engineering. The most successful approach to
date relies on the fully functional transfer of the protein glycosylation machin-
ery from C. jejuni to E. coli [173]. Based on this advance, recombinant expression
of a number of bacterial glycosyltransferases had permitted the synthesis of a
diversity of glycans that can be successfully attached to proteins based on C.
jejuni PglB enzymatic activity [51]. Despite this advances, the bacterial system
still lacks the ability to produce more appropriated human-like glycans, being
among the most important reasons the fact that bacterial glycans are substan-
tially different from their eukaryotic counterparts [146], hence engineering the
synthesis of human-like glycans in bacteria can not be based on existing bacte-
rial pathways but instead requires the assembly of a new synthetic pathway.
The main goal of this project consisted on engineering the synthesis of the
trimannose core in bacteria, serving as proof of principle and starting point for
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engineering the synthesis of fully sialylated human-like glycans in E. coli, con-
tributing to the solution of the glycan problem in bacterial systems for produc-
tion of therapeutic proteins.
1.3 The trimannose core
The virtual ubiquity of the trimannose core in eukaryotic N-glycans implies that
the synthesis of most human N-linked glycans can be achieved by extension
of this relatively simple structure. Taking this into account, engineering the
synthesis of the trimannose core in E. coli constitutes both, a proof of concept for
the technical possibility of synthesizing more complex glycans, and an obligated
first set of reactions preceding the synthesis of fully humanized glycans.
To date, it has not been reported a set of bacterial glycosyltransferases that
would permit the synthesis of the trimannose core. This limits the possibilities
to the eukaryotic domain where these glycosyltransferases have been classified
as part of the Asparagine linked glycosylation (Alg) pathway and consequently
all of them share the collective “Alg” designation [25]. Given the best stud-
ied members of these Alg group of proteins are from Saccharomyces cerevisiae,
glycosyltransferases from this organism are the obvious first candidates for the
engineering of the trimannose core synthesis pathway in bacteria. Additional
reasons include the availability of the genetic material, the lack of introns in
the specific genes encoding for these glycosyltransferases which facilitates the
cloning process, and preceding studies showing that some of these Alg enzymes
from S. cerevisiae could be expressed in E. coli [35, 122]. The following subsec-
tions provide a brief description of each of the S. cerevisiae glycosyltransferases
involved in the synthesis of the trimannose core, as well as additional informa-
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tion respect to the expression of these enzymes in E. coli.
1.3.1 Alg7
The first step in the synthesis of eukaryotic glycans is the attaching of of
phospho-GlcNAc to a lipid carrier (dolichol) which is embedded in the mem-
brane of the ER [25]. This reaction is catalyzed by the GlcNAc-1-phosphate
transferase Alg7 [133]. Probably Alg7 is the less studied glycosyltransferase in
the trimannose core synthesis pathway. There is no experimental data about its
membrane topology, although hydrophobicity analyses predict at least 8 trans-
membrane domains [142]. Interestingly, Alg7 shows relatively high positional
identity with its bacterial and archaeal homologs, suggesting the presence of
Alg7 homologs in all three domains of life [142].
This homology is specially important when taking into account Alg7 theo-
retical membrane topology. It has been reported extensively the difficulty in
recombinant expression of membrane associated proteins, particularly when
those proteins are from eukaryotic origin and the target host is a bacterium
[16, 43, 50, 100, 113, 175]. Fortunately, expression of Alg7 is not required in
E. coli given a functional homolog, WecA, is already present in this host, hav-
ing the inherent advantage of being a native enzyme as well as the ability to
recognize the bacterial lipid carrier (undecaprenol or bactoprenol) as its natural
substrate.
1.3.2 WecA
Analogous to Alg7, WecA also play a role in the initiation of the synthesis of cer-
tain bacterial glycans. WecA, also a GlcNAc-1-phosphate transferase, attaches
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the first phospho-GlcNAc to bactoprenol, serving mainly as starting point for
the synthesis of O-antigens and the enterobacterial common antigen [4]. As ex-
pected, WecA is also a membrane protein, having 11 transmembrane domains
experimentally confirmed.
Given this features, it becomes obvious that WecA is the best candidate for
initiating the synthesis of the trimannose core in E. coli. Also, given the preva-
lence of O-antigens and the enterobacterial common antigen on cells surface, we
hypothesized that natural expression levels for WecA should also be enough for
the production of adequate levels of the trimannose core.
1.3.3 Alg13 and Alg14
Addition of a second GlcNAc to the nascent glycan is catalyzed by a complex
conformed by Alg13 and Alg14, where the active site is located on the Alg13
subunit and Alg14 serves as an anchor to the ER membrane [59]. Evidence also
suggests that interaction between these two subunits is necessary for catalytic
activity, given an Alg14 knock out compromises viability in S. cerevisiae indicat-
ing that Alg13 by itself can not catalyze the addition of GlcNAc in a proper way
[57].
Alg13 is a soluble protein localized in the cytoplasm, which can form
oligomers depending on its concentration. Its 3D structure has been solved and
its sequence shows homology to the catalytic domain of bacterial MurG [177]. It
has been also concluded that it is recruited by Alg14 to the cytoplasmic face of
the ER membrane by specific hydrophobic interactions between its N-terminus
and Alg14 C-terminus [57, 59].
On the other hand, Alg14 is a membrane protein that can be found an-
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chored to the cytoplasmic face of the ER membrane. Its membrane topology
has been established, concluding that it has 1 transmembrane domain with the
N-terminus facing the ER lumen, and 2 membrane associated domains [8]. A
complex conformed by Alg7, Alg13 and Alg14 has been reported [121], where
Alg14 seems to be the central structure recruiting Alg13 from the cytoplasm and
interacting with Alg7 thanks to one of its membrane associated domains and its
N-terminal region [103]. The 3D structure of Alg14 has not being determined
experimentally. However, thanks to its homology to the membrane domain of
bacterial MurG and with help of the previously established structure of Alg13,
a good approximation has been established based on computational structure
analyses [103].
1.3.4 Alg1
Transfer of the first mannose residue to the early trimannose core is catalyzed by
Alg1, a β1,4-mannosyltransferase. Its catalytic activity was identified 30 years
ago [73]. However, our knowledge about this particular enzyme is still very
limited. Alg1 is a membrane protein which proposed topology (not confirmed
experimentally) consists of 4 transmembrane domains located towards the N-
terminus and a soluble C-terminus facing the cytoplasm [58]. Notably, the N-
terminus of Alg1 is not required for catalytic activity, and indeed, a soluble ver-
sion of Alg1 lacking its transmembrane domain have been shown to be active
in vitro [137].
Interestingly, in a simlar way to Alg14, Alg1 plays the role of central enzyme
in a multiple unit complex comprised of Alg1, Alg2 and Alg11. Since it has been
suggested that Alg2 and Alg11 do not interact with each other, Alg1 is most
likely to be responsible for the complex assembly. Furthermore, Alg1 happens
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to form dimers that later interact with Alg2 and Alg11 [58].
For the effects of this study, the most important feature about Alg1 is that
it can be expressed recombinantly in E. coli [35]. Moreover, after lysing cells,
activity of recombinant Alg1 was confirmed in vitro [137]. Although, In vivo
activity in E. coli has not been shown before our study.
1.3.5 Alg2
The trimannose core structure is completed by addition of 2 mannose residues
by Alg2, a dual function α1,3 and α1,6-mannosyltransferase [122]. As is the case
for Alg1, the knowledge about Alg2 is still relatively limited, perhaps because
it is an essential protein for many eukaryotes, constraining the possibilities for
its analysis in vivo. Alg2 is also a membrane protein, which membrane topology
has been experimentally confirmed. Studies suggest that it has 2 transmem-
brane domains at the N-terminus, a long soluble domain facing the cytoplasm,
and 2 additional membrane-associated domains at the C-terminus [81]. It is
also interesting that this glycosyltransferase does not require any of the two
N-terminal transmembrane domains for its catalytic activity, while the same is
true for the C-terminal membrane associated domains. However, deletion of all
membrane domains seems to render the protein unstable [81].
As mentioned before, Alg2 is part of a complex conformed by Alg1, Alg2 and
Alg11 [58] and its catalytic domain is most likely localized in the cytoplasmic
soluble domain [81].
Finally, and of particular interest in this project, Alg2 has been expressed re-
combinantly in E. coli as a fusion to the C-terminus of Thioredoxin. Subsequent
experiments demonstrated that membranes recovered from this E. coli strain
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showed catalytic activity consistent with that expected for Alg2 [122]. Once
again, In vivo activity in E. coli has not been shown before our study.
1.3.6 Sugar nucleotides: substrates for glycosyltransferases
Glycan synthesis requires more than just expression of glycosyltransferases.
Carbohydrate subunits are provided by highly energetic compounds denom-
inated nucleotide sugars. In the particular case of the trimannose core syn-
thesis, only two sugar nucleotides are required: Uridine Diphosphate N-
acetylglucosamine (UDP-GlcNAc) and Guanine Diphosphate Mannose (GDP-
Man).
UDP-GlcNAc
UDP-GlcNAc is a substrate for both WecA and the Alg13-Alg14 complex. In
E. coli, it is one of the precursors for peptidoglycan synthesis, so the endoge-
nous pool of this sugar donor is considered to be enough for the engineering of
glycan synthesis [141]. Also, the native synthesis pathway for regeneration of
UDP-GlcNAc stocks has been shown to be efficient enough, so it should not be
necessary to provide this precursor alongside with the growth medium [34].
GDP-Man
In E. coli, GDP-Man is synthesized de novo by two enzymes, ManB and ManC,
using mannose-6-phosphate as substrate [160]. GDP-Man is then mainly used
for synthesis of GDP-Fuc (Fuc: fucose) by two additional enzymes, GMD and
WcaG, as part of the colanic acid synthesis pathway [44] hence GDP-Man does
not accumulate in E. coli given its conversion into GDP-Fuc [160]. However,
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there are several possible strategies for increasing the GDP-Man pool, like over-
expression of RscA (a positive regulator for the colanic acid pathway), overex-
pression of ManB and ManC, and deletion of the gmd gene [141].
1.3.7 Synthesis of the trimannose core in E. coli
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Figure 1.5: Synthesis of the trimannose core in E. coli. The highlighted residues constitute
the “common core” or “trimannose core” (adapted from [115]). UDP: uridyl
diphosphate, GDP: guanidyl diphosphate
The main hypothesis in this project is that the trimannose core can be syn-
thesized in E. coli given the necessary glycosyltransferases are recombinantly
expressed and the cytoplasmic concentration of required sugar nucleotides can
be maintained at appropriate levels. After that, C. jejuni PglB would transfer the
trimannose core to a target protein in the periplasm. Figure 1.5 shows a diagram
summarizing this hypothesis.
The following chapters show how the synthesis of the trimannose core was
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achieved, how it can be attached in vivo to model proteins, and some of the
many directions this process may take respect to synthesis of complex glycans,
optimization of the current process and alternative applications.
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CHAPTER 2
AN ENGINEERED EUKARYOTIC PROTEIN GLYCOSYLATION
PATHWAY IN ESCHERICHIA COLI1
2.1 Introduction
N-linked protein glycosylation is an essential and conserved process that oc-
curs in the endoplasmic reticulum of eukaryotes [25]. It is the most common
post-translational modification of eukaryotic proteins and can affect many im-
portant protein properties [67]. N-linked glycosylation is not limited to eukary-
otes, however, as bona fide N-linked glycosylation pathways have been discov-
ered in proteobacteria [162] and transferred to E. coli. There are several notable
differences between bacterial and eukaryotic N-glycosylation systems. First,
bacteria assemble oligosaccharides on undecaprenyl pyrophosphate (Und-PP)
in the cytoplasmic membrane whereas eukaryotes use dolichyl pyrophosphate
(Dol-PP) in the ER membrane. Second, the N-X-S/T consensus sequence for N-
glycosylation in eukaryotes can be extended to D/E-X−1-N-X+1-S/T (X−1, X+1
6= P) in bacteria [88]. Third, and most importantly, bacterial N-glycans [187] are
completely distinct from any known eukaryotic glycan. As a result, glycopro-
teins derived from existing bacterial expression systems have been restricted
to bioconjugate vaccines [51, 76] or glycoproteins that require extensive in vitro
modification [147]. The construction of a eukaryotic glycosylation pathway in
E. coli that generates human-like N-glycans has remained an elusive challenge
despite years of speculation [30, 127, 178].
To address this challenge, we focused on engineering E. coli to produce
mannose3-N-acetylglucosamine2 (Man3GlcNAc2) eukaryotic glycans. We chose
1Adapted with permission from Valderrama-Rincon, J. D. et al. An engineered eukaryotic
protein glycosylation pathway in Escherichia coli. Nature Chemical Biology (2012).
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Man3GlcNAc2 because it is: (i) the core structure common to all human N-
glycans; (ii) the predominant N-glycan produced by baculovirus-insect cells
[89], carrot root plant cells [9], and Tetrahymena thermophila [179], all of which
yield glycans that are fit for pre-clinical and clinical products; and (iii) the min-
imal glycan required for a therapeutic glycoprotein currently on the market
[170]. To generate Man3GlcNAc2 glycans, a synthetic pathway was designed
that we predicted would assemble the glycan on Und-PP in the cytoplasmic
membrane of E. coli (figure 2.1a). The first step in this pathway involved the en-
dogenous integral membrane protein WecA, a glycosyltransferase (GTase) that
catalyzes the transfer of GlcNAc-1-phosphate to undecaprenyl phosphate (Und-
P). The native GlcNAc-PP-Und intermediate served as the foundation for the
Man3GlcNAc2 structure.
2.2 Results and discussion
To extend the glycan, several heterologous GTases from Saccharomyces cerevisiae
were selected because these have been solubly expressed in E. coli [35, 122, 177]
and in some cases the expressed enzymes were active in vitro [35, 122]. Specifi-
cally, for addition of the second GlcNAc residue to GlcNAc-PP-Und, we chose
the S. cerevisiae β1,4-GlcNAc transferase that is comprised of the subunits Alg13
and Alg14. In yeast, Alg14 is an integral membrane protein that functions as a
membrane anchor to recruit soluble Alg13 to the cytosolic face of the ER mem-
brane, where synthesis of GlcNAc2-PP-Dol occurs [18]. For the subsequent
steps, we employed S. cerevisiae β1,4-mannosyltransferase Alg1, which specifies
the addition of the first mannose to the glycan [35], and the bifunctional manno-
syltransferase Alg2, which carries out the subsequent addition of both an α1,3-
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Figure 2.1: Engineering eukaryotic glycan biosynthesis in E. coli. (a) Schematic of the syn-
thetic pathway for synthesis of a trimannosyl core glycan and transfer to
acceptor sites in target proteins. Enzyme names in black are native to E.
coli; enzyme names in red are heterologous. See text for details. Glycan in
brackets to the right of open arrows depicts terminally sialylated structure
common in human glycoproteins, but outside the scope of this study. (b)
Plasmid pMQ70-YCG for the biosynthesis of a trimannosyl core glycan and
pMWO7-YCG-pglBCj for producing a trimannosyl core glycan with the C.
jejuni OTase PglB, were constructed in plasmids pMQ70 and pMW07, re-
spectively.
and α1,6-mannose in a branched configuration [122]. Assembly of a functional
Man3GlcNAc2 synthesis pathway required expression and localization of these
enzymes in the inner membrane of E. coli. This represented a non-trivial task
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given that the functional expression of even one non-enzyme eukaryotic mem-
brane protein in E. coli can pose a significant challenge [85]. When co-expressed
in E. coli, both Alg 13 and Alg14 were detected in the membrane fraction while
Alg13 was also evident in the soluble fraction (figure 2.2), consistent with their
localization in yeast. Likewise, both Alg1 and Alg2 were detected in the mem-
brane fraction (figure 2.2).
ins sol mem ins sol mem
Alg13 Alg14 Alg1 Alg2
ins sol mem ins sol mem
25kDa 25kDa
50kDa 75kDa
Figure 2.2: Expresion of S. cerevisiae Alg13, Alg14, Alg1 and Alg2 in E. coli. Western blot
analysis of insoluble (ins), soluble (sol) and membrane (mem) fractions iso-
lated from MC4100 gmd::kan cells carrying pMQ70-YCG. All proteins mi-
grated according to their predicted molecular weights. Alg14 was detected
using anti-FLAG antibodies; the rest were detected using anti-His antibod-
ies as described in the Supplemental Methods.
To determine if the membrane-localized Alg enzymes were oriented cor-
rectly with their active sites on the cytoplasmic face of the inner membrane
and expressed as active enzymes capable of producing Man3GlcNAc2 on Und-
PP, we constructed plasmid pMQ70-YCG that encoded a synthetic gene cluster
comprised of alg13, alg14, alg1 and alg2 (figure 2.1 1b). To increase the avail-
ability of the GDP-mannose substrate for Alg1 and Alg2, the gene encoding
GDP-mannose dehydratase was deleted from E. coli strain MC4100. This dele-
tion prevents the conversion of GDP-mannose to GDP-4-keto-6-deoxymannose
in the first step of GDP-L-fucose synthesis [141]. To assay glycan synthesis, we
exploited the fact that bacterial cell surfaces can display engineered oligosac-
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charide structures in their lipopolysaccharide layer [52, 77, 186]. This approach
is dependent upon the O-antigen ligase WaaL, which catalyzes the transfer of
Und-PP-linked oligosaccharides to the E. coli lipid A core. These oligosaccha-
rides are then shuttled to the cell surface where they can be conveniently labeled
with fluorescent probes [52, 77].
Upon labeling with fluorescent Canavalia ensiformis concanavalin A (ConA),
a lectin that binds terminal α-mannose, MC4100 gmd::kan cells expressing the
synthetic pathway but not empty vector control cells became highly fluorescent
(figure 2.3a). The fluorescence was clearly localized on the cell surface (figure
2.4). Importantly, cell fluorescence was significantly diminished in the absence
of alg1 or alg2 (figure 2.3a), confirming that terminal α-mannose residues on
the cell surface were dependent on these enzymes. Likewise, when the syn-
thetic pathway was expressed in MC4100 gmd::kan that also lacked waaL, cells
were minimally fluorescent (figure 2.3a). Taken together this analysis suggests
that oligosaccharides with terminal α-mannose residues were synthesized and
shuttled to the cell surface via the WaaL enzyme. As an important corollary, a
native E. coli flippase (e.g., Wzx) must be involved since WaaL-dependent trans-
fer to lipid A requires that Und-PP-linked oligosaccharides are available on the
periplasmic face of the cytoplasmic membrane [5].
To verify the structure of the glycans, lipid-linked oligosaccharides (LLOs)
were extracted and subjected to acid hydrolysis to remove glycans. The re-
leased glycans were permethylated and characterized by matrix-assisted laser
desorption/ionization tandem time-of-flight (MALDI-TOF/TOF) analysis. The
MALDI-MS spectrum revealed Hex3HexNAc2 as the primary oligosaccharide,
which is consistent with the expected Man3GlcNAc2 glycan. In addition,
Hex2HexNAc2 and Hex4HexNAc2 oligosaccharides were detected (figure 2.3b,
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Figure 2.3: Characterization of LLOs produced by glycoengineered E. coli. (a) Flow cyto-
metric analysis of E. coli MC4100 gmd::kan or MC4100 gmd::kan ∆waaL cells
carrying plasmids as indicated. Cells were labeled with ConA-AlexaFluor
prior to flow cytometry. Median cell fluorescence (M) values are given for
each histogram. (b) MALDI-MS profile of permethylated glycans released
from LLOs by acid hydrolysis. LLOs were extracted from E. coli MC4100
gmd::kan (top panel) or MC4100 gmd::kan ∆waaL cells (bottom panel) car-
rying plasmid pMQ70-YCG. The major signal at m/z 1171 corresponds to
[M+Na]+ of Hex3HexNAc2.
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Light Green Merge
gmd::kan
gmd::kan
ΔwaaL
Figure 2.4: ConA-AlexaFluor labeling. ConA-AlexaFluor labeling of MC4100 gmd::kan
(top panels) or MC4100 gmd::kan ∆waaL (bottom panels) cells each carry-
ing plasmid pMQ70-YCG. Cells were visualized by light and fluorescence
microscopy as described in the Materials and Methods section. Panels show
phase contrast microscopy (left), fluorescence microscopy using green emis-
sion filter (center) and merge (right).
top panel). The MALDI-MS spectrum of LLOs isolated from the MC4100
gmd::kan ∆waaL strain was also consistent with the presence of Man3GlcNAc2
(figure 2.3b, bottom panel). This confirmed that the lack of cell surface labeling
observed for these cells was a result of the waaL deletion and not the inability
to synthesize oligosaccharides. Finally, released glycans analyzed by 1H NMR
spectroscopy were consistent with the eukaryotic core glycan Manα1-3(Manα1-
6)-Manβ1-4-GlcNAcβ1-4-GlcNAc (figure 2.5 and 2.6).
We next investigated whether Man3GlcNAc2 glycans could be transferred
to secretory glycoproteins by a heterologous oligosaccharyltransferase (OTase)
in vivo. To our knowledge, no eukaryotic OTases have been functionally ex-
pressed in E. coli. Therefore, we focused our attention on PglB from C. jejuni
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Figure 2.5: 1H NMR analysis of glycans released from extracted LLOs.. (a) Anomeric region
of the resolution-enhanced 1-D proton spectrum acquired at 25◦C. (b) Partial
2-D gCOSY spectrum acquired at 25◦C. This analysis confirms the identity
of every single carbohydrate unit in the glycan as well as the nature of the
linkages between them.
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Figure 2.6: Mass spectrometry analysis of glycans released from LLOs and glycoprotein. (a)
MALDI-TOF/TOF MS2 sequencing of N-glycans at m/z 1171. X/Y ion series
at m/z 300/328, 545/573, 953/981, coupled with B/Y ion pair at m/z 894/300,
showed the presence of biantennary trimannosyl-core N-glycan structure.
D ions at m/z 431 and 880 further confirmed the structure. (b) MALDI-MS
profile of glycans released from scFv13-R41x−DQNAT by PNGaseF (top panel)
and treated further with C. ensiformis α-exomannosidase (bottom panel) to
determine the identity of terminal hexose units. This confirms that the two
terminal mannose residues were α-linked to the first mannose residue.
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(PglBCj) because it is the best characterized bacterial OTase [102] and is ca-
pable of handling diverse Und-PP-linked oligosaccharides as substrates in E.
coli [51, 76, 172]. For secretory glycoprotein targets, we initially examined (i)
E. coli maltose binding protein (MBP) which is a native periplasmic protein
and (ii) anti-β-galactosidase single-chain antibody fragment called scFv13-R4
that was modified with an N-terminal co-translational export signal from E.
coli DsbA [144]. Each of these target proteins was modified at the C-terminus
with four tandem repeats of the bacterial glycan acceptor motif DQNAT [52].
MC4100 gmd::kan ∆waaL cells were transformed with plasmids encoding one of
these target proteins, the Man3GlcNAc2 synthesis pathway, and PglBCj . Follow-
ing co-expression, a low but consistent amount of MBP4x−DQNAT and scFv13-
R44x−DQNAT was bound by ConA, in contrast to the same target proteins pro-
duced in cells carrying an inactive PglBCj mutant [173] (figure 2.7a). Further,
when target proteins from cells with wildtype PglBCj were treated with pep-
tide:N-glycosidase F (PNGase F), an amidase that specifically cleaves between
a reducing-end GlcNAc and asparagine, binding by ConA was eliminated (fig-
ure 2.7a). Thus, α-mannose-containing glycans were linked specifically to as-
paragines in the target proteins by PglBCj . PNGase F-released glycans from gly-
cosylated scFv13-R44x−DQNAT were characterized by MALDI-TOF/TOF analysis
and the predominant N-linked glycan was Hex3HexNAc2 along with a lesser
amount of Hex4HexNAc2 (figure 2.7b). In addition, a version of scFv13-R4
that carried a single C-terminal DQNAT sequon was subjected to nonspecific
proteolytic digestion with Pronase E and permethylation prior to MS analy-
sis [101]. The major ion seen at m/z 1282 was consistent with Man3GlcNAc2-
Asn, wherein the asparagine residue underwent β-elimination during the per-
methylation procedure (figure 2.7c) [101]. MS2 sequencing of the glycan at m/z
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1171 confirmed the biantennary trihexosyl structure (figure 2.8a) and 1H NMR
analysis on PNGase F-released glycans was consistent with Manα1-3(Manα1-
6)-Manβ1-4-GlcNAcβ1-4-GlcNAc (figures 2.5 and 2.9).
The increased abundance of the larger glycoform in the protein samples
relative to the LLO samples may have been due to differences in the culture
conditions and/or enrichment of higher mannose glycans during ConA affinity
chromatography. When PNGase F-released glycans were treated with Canavalia
ensiformis α-exomannosidase to specifically hydrolyze terminal α-mannose
residues, the MALDI-MS spectrum showed the emergence of HexHexNAc2
as the predominant glycoform at the expense of both Hex3HexNAc2 and
Hex4HexNAc2 (figure 2.8b). Consistent with this MS spectrum, NMR anal-
ysis revealed a residue with H-1 (5.080 ppm) and H-2 (4.065 ppm) chemi-
cal shifts consistent with an additional Man linked to one of the branching
Man residues (Fig. S3). The presence of a putative Man4GlcNAc2 is some-
what surprising because Alg2 is not known to specify the addition of man-
nose beyond Man3GlcNAc2-PP-Dol in vitro [122]. Elongation of Man3GlcNAc2
to Man4GlcNAc2 and Man5GlcNAc2 is attributed to the bifunctional Alg11
enzyme. It should be noted, however, that both Man3GlcNAc2-PP-Dol and
Man4GlcNAc2-PP-Dol accumulated in a S. cerevisiae alg11 mutant [33], suggest-
ing that Alg1 or Alg2 may catalyze Man4GlcNAc2-PP-Dol production.
To determine whether Man3GlcNAc2 glycans could be transferred to eu-
karyotic glycoproteins, we next attempted to glycosylate: (i) the Fc domain
of human IgG1 at its conserved N297 glycosylation site, (ii) bovine ribonucle-
ase A (RNaseA) at its N34 acceptor site, and (iii) the placental variant of hu-
man growth hormone (hGHv) at its N140 glycosylation site. The open read-
ing frames encoding these proteins were cloned downstream of an N-terminal
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Figure 2.7: Transfer of eukaryotic glycans to target proteins in E. coli. (a) Western blot anal-
ysis of MBP4x−DQNAT and scFv13-R44x−DQNAT affinity purified from E. coli
MC4100 gmd::kan ∆waaL cells carrying pMWO7-YCG-PglBCj or pMWO7-
YCG-PglBCjmut as indicated. Proteins isolated from cells expressing wild-
type PglBCj were further treated with PNGase F for removal of N-linked
glycans. Polyhistidine tags on the proteins were detected using anti-His an-
tibodies while mannose glycans on the proteins were detected using ConA.
(b) MALDI-MS profile of permethylated glycans released from scFv13-
R44x−DQNAT by PNGase F treatment. The major signal at m/z 1171 corre-
sponds to [M+Na]+ of Hex3HexNAc2. (c) MALDI-MS profile of perme-
thylated glycopeptides generated by digestion of scFv13-R41x−DQNAT with
Pronase E. The major signal at m/z 1282 corresponds to the permethylation
product of Hex3HexNAc2-N, where the asparagine residue underwent β-
elimination during the permethylation procedure (see inset).
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No. Residue Position Chemical S hift (ppm)a NOE
1 2 3 4 5 6
I 4-α-GlcNAc 1 5.183 3.88 3.65 n.d. n.d. n.d.
II α-Man 4 5.094 4.059 3.89 n.d. n.d. n.d. VI-3
III ? ? 5.080 4.065 n.d. n.d. n.d. n.d.
IV ? ? 5.042 4.065 n.d. n.d. n.d. n.d.
V α-Man 4’ 4.910 3.97 3.89 n.d. n.d. n.d.
VI 3,6-β-Man 3 4.777 4.25 3.75 n.d. n.d. n.d.
VII 4-β-GlcNAc 1 4.692 3.69 n.d. n.d. n.d. n.d.
VIII 4-β-GlcNAc 2 4.602 3.79 3.62 n.d. n.d. n.d.
IX Xyl * 4.473 3.29 3.55 3.78
Partial assignmet of the NMR signals
4.10/3.37
Figure 2.8: Partial assignment of the NMR signals belonging to Man3GlcNAc2 from protein-
released glycans. The chemical shifts obtained from the 2-D spectra were
consistent with the main component of the sample being Man3GlcNAc2.
This sample was available in sufficient quantity to allow acquisition of a 2-
D HSQC spectrum, which confirmed the proton peak assignments. Xylose
was determined to be a contaminant as it was not detected by MS analysis or
by NMR of glycans released from lipids. Xylose is a common contaminant
of bacterial samples.
DsbA export signal or full-lenth MBP in the case of hGHv. Since the N-X-S/T
consensus motif in eukaryotes is extended to D/E-X−1-N-X+1-S/T in bacteria
[88], we used Fc and hGHv mutants whose native glycosylation motifs were
mutated from QYNST (residues 295-299) and IFNQS (residues 138-142), respec-
tively, to DQNAT. Likewise, we used an RNaseA variant with an S32D substitu-
tion [87]. Expression of FcDQNAT, hGHvDQNAT, or RNaseA S32D in the periplasm
of E. coli cells carrying the pMWO7-YCG-PglBCj plasmid yielded clearly glyco-
sylated proteins (figure 2.10a and b). Whereas glycosylation of the structurally
flexible acceptor sites in the Fc domain and hGHv was not surprising in light
of previous studies [52, 147], RNaseA glycosylation was unexpected given that
the acceptor site is located in a structured domain that is not glycosylated by
PglBCj in vitro [87]. These data imply that PglBCj may be capable of glycosylat-
ing residues in both unstructured and structured regions of eukaryotic acceptor
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Figure 2.9: 1H NMR analysis of N-linked glycans released from purified scFv13-R44x−DQNAT.
(a) Anomeric region of the resolution-enhanced 1-D proton spectrum ac-
quired at 21◦C. (b) Partial 2-D gCOSY spectrum acquired at 21◦C. This anal-
ysis confirms the identity of every single carbohydrate unit in the glycan as
well as the nature of the linkages between them.
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proteins in vivo.
In this work, we have established glycosylation of target proteins with
Man3GlcNAc2 glycans in recombinant E. coli. This was made possible by the
functional co-expression of four membrane-bound eukaryotic enzymes and one
bacterial integral membrane protein. The significance of this result is perhaps
best reflected by the well-documented difficulties in expressing just one eukary-
otic membrane protein in E. coli [85]. The further requirement that the expressed
membrane proteins must be catalytically active would not have been predicted
from in vitro studies alone. For example, earlier in vitro studies reported
that PglBCj was not capable of utilizing chitobiose donors such as dolichyl-
pyrophosphate-GlcNAc-GlcNAc disaccharide [29]. Also, PglBCj was hardly
able to glycosylate RNaseA in vitro [87]. However, under the in vivo conditions
tested here, PglBCj was capable of transferring lipid-linked pyrophosphate-
GlcNAc-GlcNAc saccharide substrates to both unstructured and structured re-
gions of diverse targets including RNaseA.
Despite our success in reconstituting a eukaryotic glycosylation pathway in
E. coli, there remain some important challenges that will need to be overcome for
the practical application of this technology. For example, only a small fraction
(<1%) of each expressed protein was glycosylated under the conditions tested
here. With that said, the yield of glycosylated proteins has reached up to 50
µg/L in our hands and might be further improved by increasing expression in
the periplasm, relieving enzymatic and metabolic bottlenecks, and/or optimiz-
ing the glycosylation enzymes. Along these lines, simple optimization strategies
have previously been used to generate nearly 25 mg/L of bacterial glycopro-
teins in E. coli [76]. We anticipate further improvements will be achieved by
applying new glyco-display technologies in bacteria, including cell surface and
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Figure 2.10: Glycosylation of genuine human glycoproteins. (a) Western blot analysis of
FcDQNAT affinity purified from E. coli MC4100 gmd::kan ∆waaL cells carry-
ing pMWO7-YCG-PglBCj or pMWO7-YCG-PglBCjmut as indicated. Pro-
teins isolated from cells expressing wild-type PglB were further treated
with PNGase F for removal of N-linked glycans. FcDQNAT was detected
using anti-Human antibodies while mannose glycans on the proteins were
detected using ConA. (b) Western blot analysis of RNaseA S32D and MBP-
hHGvDQNAT affinity purified from E. coli MC4100 gmd::kan ∆waaL cells
carrying pMWO7-YCG-PglBCj . Proteins were loaded directly or further
treated with PNGase F for removal of N-linked glycans. RNaseA S32D and
MBP-hHGvDQNAT were each detected using anti-His antibodies while ter-
minal mannoses on protein glycans were detected using ConA. (c) Transfer
of trimannosyl glycans to target proteins by C. lari PglB. Western blot anal-
ysis of scFv13-R44x−DQNAT affinity purified from E. coli MC4100 gmd::kan
∆waaL cells carrying pMWO7-YCG-PglBCj for expressing C. jejuni PglB or
pMWO7-YCG-PglBCl for expressing C. lari PglB. Proteins were loaded di-
rectly or further treated with PNGase F for removal of N-linked glycans.
scFv13-R44x−DQNAT was detected using anti-His antibodies while terminal
mannoses on protein glycans were detected using ConA. In general, these
results show that glycosylation of genuine human glycoproteins is possi-
ble, being this system a potential platform for production of therapeutic
glycoproteins.
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phage display systems [27, 48, 52] for high-throughput screening of glycosyla-
tion phenotypes. We also believe that other OTases, such as C. lari PglB (PglBCl)
which is capable of transferring Man3GlcNAc2 (figure 2.10c) and can transfer
glycans to minimal N-X-S/T acceptor sites [148], can be optimized for improved
function. Alternatively, single-subunit eukaryotic OTases (e.g., Leishmania major
STT3 paralogues [128]) could be used that naturally use as substrates both (i) eu-
karyotic glycoproteins with minimal N-X-S/T acceptor sites and (ii) eukaryotic
glycans comprised of the trimannosyl core structure.
Since it does not have native glycosylation pathways, E. coli is the only plat-
form for glycoprotein expression that offers bottom-up synthesis of novel gly-
can structures by expression of diverse GTases and OTases. The engineering of
defined glycosylation pathways in E. coli sets the stage for further engineering of
this host for the production of vaccines and therapeutics with even more struc-
turally complex human-like glycans. Moreover, we believe glycoengineered E.
coli has the potential to serve as a model genetic system for deciphering the
glycosylation code which governs the non-template driven synthesis of diverse
glycans and their specific attachment to proteins.
2.3 Materials and methods
2.3.1 Bacterial strains and media
Antibiotic selection was maintained at: 100 µg/mL ampicillin (Amp), 25
µg/mL chloramphenicol (Cam) and 50 µg/mL kanamycin (Kan). Luria Bertani
(LB) media was used for E. coli, supplemented with glucose at 0.2% as indi-
cated. Protein expression was induced by adding L-arabinose and isopropyl
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-d-thiogalactoside (IPTG) at 0.2% and 100 mM, respectively. Yeast FY834 was
maintained on YPD media and synthetic-defined-Uracil media was used to se-
lect or maintain yeast plasmids. E. coli MC4100 (F- araD139 ∆(argF-lac)U169
flbB5301 deoC1 ptsF25 relA1 rbsR22 rpsL150 thiA) was used as the recipient
strain for genetic manipulations. To delete the gmd gene in MC4100 cells, P1vir
phage transduction was performed using standard methods and the Keio col-
lection [10]. The Kan resistance cassette was removed from MC4100 waaL::kan
cells using plasmid pCP20 [36] prior to P1vir phage transduction to obtain the
strain MC4100 gmd::kan ∆waaL.
2.3.2 Plasmid construction
Plasmid pTrc99A-alg13::alg14 was used for co-expression of yeast Alg13 and
Alg14. Plasmid pTrc99A-alg1 and pBAD(alg2)-DEST493 were used for individ-
ual expression of Alg1 and Alg2, respectively. pBAD(alg2)-DEST49 was a gen-
erous gift from Dr. Barbara Imperiali, while pTrc99A-alg13::alg14 and pTrc99A-
alg1 were constructed using standard techniques. alg13, alg14 and alg1 genes
were amplified from Saccharomyces cerevisiae genomic DNA. A C-terminal 6x-
His tag was added to Alg1 and Alg13 while an N-terminal FLAG epitope tag
was added to Alg14. An additional ribosomal binding site was introduced in
front of alg14 to allow bicistronic expression. Plasmids pTrc99A-MBP4x−DQNAT,
pTrc99A-ssDsbA-scFv13-R44x−DQNAT and pTrc-ssDsbA-FcDQNAT were used for
expression of glycoproteins, as reported previously [52]. Plasmid pTrc99A-
ssDsbA-scFv13-R44x−DQNAT was constructed as described for pTrc99A-ssDsbA-
scFv13-R44x−DQNAT. The remaining plasmids were constructed using standard
homologous recombination in S. cerevisiae as previously described [149]. Briefly,
pMQ70-YCG (see figure 2.1) was constructed by first PCR amplifying the genes
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alg13, alg14, alg1, and alg2 from S. cerevisiae genomic DNA with primers con-
taining appropriate regions of overlap. PCR products and the linearized vector
pMQ70 were used to transform yeast strain FY834. Constructs assembled in
yeast were electroporated into E. coli for verification via PCR, restriction en-
zyme digestion and/or sequencing. For glycosylation studies, vector pMW07
was similarly generated from pMQ70 by replacing the origin (ori) and antibiotic
resistance cassette with the p15a ori and the cat gene for resistance to Cam. Plas-
mid pMW07 was the host vector for pMWO7-YCG-PglBCj encoding C. jejuni
PglB amplified from (i) pACYC-pgl (see figure 2.1) or (ii) a synthesized, codon
optimized version of C. jejuni PglB (Mr. Gene), (iii) pMWO7-YCG-PglBCjmut
amplified from pACYC-pgl pglBmut encoding an inactive PglB variant [173]
and (iv) pMWO7-YCG-PglBCl encoding a codon optimized C. lari PglB synthe-
sized for this work (Mr. Gene). The codon optimized version of PglBCj showed
a modest improvement over the wild-type enzyme (~15% increase in yield,
data not shown) and was used to generate glycosylated scFv13-R41x−DQNAT for
Pronase E digestion, scFv13-R44x−DQNAT for NMR analysis, RNAseA S32D for
Western blot, and for the comparison of PglBCj and PglBCl (figure 2.6c). Plasmid
pTrc99Y was generated from pTrc99A by adding the yeast origin and URA selec-
tion cassette from pMQ80 [149]. The gene encoding the bovine RNAseA S32D
mutant was amplified from pMIK817 for pTrc99Y-ssDsbA-RNAseA S32D. The
gene encoding hGHv was synthesized (Mr. Gene) and amplified for pTrc99Y-
MBP-hGHvDQNAT. pMQ70-YCG∆alg1 and pMQ70-YCG∆alg2 were derived
from pMQ70-YCG using standard digestion and ligation.
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2.3.3 Isolation of membranes and LLOs
Membranes were isolated similarly to the method of Marani et al [106]. For
LLOs extraction, overnight cultures were diluted 1:100 into LB broth and incu-
bated at 37◦C with shaking (250 rpm) until reaching A600 ~0.6. Protein expres-
sion was then induced with 0.2% L-arabinose and cells were incubated at 30◦C
overnight in screw-capped flasks filled with media. Lipid-linked oligosaccha-
rides (LLOs) were extracted and partially purified as described previously [56].
Briefly, the LLO extraction protocolwas based on a total lipid extraction proto-
col using chloroform:water (2:1) as described previously [53]. This solvent mix-
ture extracts the most hydrophobic lipids, leaving LLOs in the precipitate. The
precipitate was washed with water to remove hydrophilic molecules and then
LLOs were extracted preferentially using chloroform:methanol:water (10:10:3).
Contaminating oligosaccharides not attached to lipids were removed by adsorb-
ing extracted LLOs on DEAE-cellulose. LLOs were then recovered from DEAE-
cellulose using an ammonium acetate solution. After releasing glycans from
LLOs by acid hydrolysis, a butanol/water mixture was used to extract glycans
to the water phase while lipids remained in the butanol phase. Finally, two
ionic exchange resins (AG50W-X8 (Sigma) and AG1-X8 (BioRad)) were used for
removing the remaining salts.
2.3.4 Flow cytometry
E. coli cells were incubated at 30◦C overnight in LB supplemented with 0.2%
L-arabinose in filled, sealed culture tubes. Cells were pelleted, washed, resus-
pended in (PBS) and boiled for 10 min. 2.5 µg/mL Canavalia ensiformis Con-
canavalin A (ConA)-AlexaFluor was added to the samples before incubation in
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the dark for 15 min at room temperature. 100 µL of each sample were analyzed
using a FACSCalibur (Becton Dickinson). Median fluorescence was determined
from 10,000 events. For microscopy, 5 µL of cells with ConA-AlexaFluor were
imaged on a Zeiss Axioskop 40 and all images were captured under bright field
illumination or UV illumination.
2.3.5 Glycoprotein expression and purification
MC4100 gmd::kan∆waaL cells were freshly transformed with pYCG-PglBCj , and
a plasmid for glycoprotein expression. Overnight cultures were diluted 1:100
into LB broth with antibiotics and incubated at 30◦C with shaking (250 rpm) un-
til reaching A600 ~3. Cultures were then induced with IPTG and L-arabinose,
and returned to 30◦C for ~16 h. Cells were pelleted, frozen, resuspended in
ConA column buffer (50 mM HEPES, 0.15 M NaCl, 0.1 mM CaCl2, 0.01 mM
MnCl2, pH 7.0) with 1.0 mg/mL lysozyme and disrupted by either sonication
(for Western blot analysis) or with a single pass through a microfluidizer (Mi-
crofluidics #110Y) at 20,000 psi (for MALDI-MS analysis). To isolate glycopro-
teins, clarified lysates (10 min at 18,000xg at 4◦C) were subject to affinity chro-
matography with a HiTrap ConA 4B column (GE Healthcare). Eluates were
concentrated with 10-kDa MWCO columns (Sartorius Vivaspin20), diluted 40x
in Ni-NTA buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0),
and again concentrated to 1 mL. His-tagged glycoproteins were then purified
with a Qiagen Ni-NTA Kit per manufacturers instructions. Fcs were then pu-
rified with a Nab Protein A/G Spin Kit (Thermo Scientific) per manufacturers
instructions. For MALDI-TOF MS, eluate was dialyzed in a Slyde-A-Lyzer 3500
MWCO cassette (Thermo Scientific) in 1.8 L deionized water (24 h, three volume
replacements). Proteins from negative control cells expressing PglBCjmut were
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processed identically and no glycoprotein could be detected by ConA affinity,
as expected (data not shown). Aglycosylated PglBCjmut control samples used in
Western blot analysis were purified directly with a Qiagen Ni-NTA Kit or Nab
Protein A/G Spin Kit per manufacturers instructions.
2.3.6 Western blot analysis
Purified protein samples were separated using 12% SDS-PAGE gels and trans-
ferred to PVDF membranes. Proteins that harbored 6x-His affinity tags were
detected with a monoclonal anti-polyhistidine-horse radish peroxidase (HRP)
conjugate (Sigma), a monoclonal anti-His (C-term) antibody (Invitrogen), or
a monoclonal anti-FLAGr M2 antibodies (Stratagene), per manufacturers in-
structions. Human Fcs were detected by anti-Human HRP conjugate antibodies
(Promega). Protein-conjugated glycans were detected with 2.5 µg/mL ConA-
HRP conjugate (Sigma). To remove N-linked glycans prior to Western blotting,
purified glycoproteins were incubated with 5,000 units of PNGase F (New Eng-
land BioLabs) at 37◦C for 1 hr. Samples that were not treated with PNGase F
were handled identically except PNGase F was omitted from the solution.
2.3.7 Glycosylation characterization by mass spectrometry and
NMR
Glycans were released from E. coli LLOs as described previously [56]. N-
glycans were released from glycoproteins by treating 100 µg of purified scFv13-
R44x−DQNAT or scFv13-R41x−DQNAT with trypsin followed by PNGase F diges-
tion in 50 mM ammonium bicarbonate, pH 8. Glycans were collected as flow-
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through after SepPak C18 (Waters) separation. Some glycans were further di-
gested with C. ensiformis α-exomannosidase in 50 mM ammonium acetate, pH
4.5, followed by further desalting steps using a carbon column (envi-carb SPE
tube, Supelco). The mannosidase treatment was halted prior to completion to
fully examine the glycan intermediates. Permethylation of glycans was per-
formed as described [79]. Asparagine-linked glycans were analyzed as de-
scribed elsewhere [101] with permethylation. MALDI-MS profiles were ac-
quired using a 4800 MALDI-TOF/TOF (Applied Biosystems) in positive ion
reflectron mode (500-4000 Da mass range). MALDI-MS/MS sequencing of per-
methylated glycans was performed in positive ion reflectron mode. Air was
used as the collision gas. Structure assignment was according to the method
of Yu et al [188]. All NMR analysis was performed at the Complex Carbohy-
drate Research Center (University of Georgia, Athens, GA). Briefly, 1-D Proton,
TOCSY and NOESY NMR spectra, run with water presaturation, and gradient
enhanced COSY and HSQC spectra were acquired on a Varian Inova-600 MHz
spectrometer, equipped with a cryoprobe, at 21◦C (for protein-released glycans)
and at 25◦C (for lipid-released glycans). Chemical shifts were measured relative
to internal acetone (δH = 2.218 ppm, δC = 33.0 ppm).
2.4 Contributions to this chapter
Juan D. Valderrama-Rincon and Adam C. Fisher designed research, performed
research, analyzed data and wrote the paper. Judith H. Merritt designed re-
search and performed research. Yao-Yun Fan performed MS analysis and ana-
lyzed data. Craig A. Reading and Krishan Chhiba performed research. Chris-
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CHAPTER 3
FUNCTIONAL EXPRESSION OF ALG11, A GLYCOSYLTRANSFERASE
FROM SACCHAROMYCES CEREVISIAE, IN ESCHERICHIA COLI
3.1 Introduction
As glycobiology is becoming an increasingly important field, the poor avail-
ability of affordable glycans has been a persistent limitation for several studies.
While chemoenzymatic synthesis is the prevalent source of glycans for the field
[19], bacterial in vivo synthesis has the potential to become a relatively inex-
pensive and versatile source for a variety of glycans. According to this, several
strategies have been developed for production of diverse carbohydrates and
glycans in engineered microorganisms [141]. However, given most glycosyl-
transferases are membrane proteins, their recombinant expression is often dif-
ficult [16, 43, 50, 100, 113, 175] and most of the time they require engineering
of the host as well as engineering of the protein itself, like fusion to folding and
membrane integration partners [72, 113, 120, 139, 184], before proper expression
is achieved.
In general, it has been hypothesized that an ideal fusion partner for recom-
binant production of membrane proteins should be able to help the protein to
insert properly in the membrane while bypassing the translocation machinery,
so toxicity derived from translocon overloading would not be an issue [139].
One interesting example of such a partner is Mistic, a 13kDa protein from Bacil-
lus subtilis which has been used successfully for overproduction of recombinant
membrane proteins in bacteria [47, 139], constituting a promising fusion partner
for glycosyltransferases.
Despite the challenges associated to expression of this glycosyltransferases,
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therapeutic importance of glycans have encouraged a number efforts toward
the synthesis of human-like glycans in several kinds of non-human cells more
suitable for high scale production like Chinese hamster ovary cells, plant cells,
insect cells and yeast cells. Synthesis of human-like glycans in these cells
has been achieved mainly by recombinant expression of human glycosyltrans-
ferases [26, 69, 78, 180]. However, synthesis of such glycans in bacterial cells has
not been reported until recently, when eukaryotic-like glycans were produced
using E. coli as host [167]. In this case, the trimannose core, a common struc-
ture found on the vast majority of eukaryotic N-linked glycans [115, 146] was
synthesized in E. coli by recombinant expression of several S. cerevisiae glyco-
syltransferases alongside with deletion of the gmd gene. This is the first suc-
cessful attempt to synthesize the trimannose core in bacteria, and as such, this
study opened several interesting possibilities, like further elongation of this ba-
sic structure to obtain more complex human-like glycans.
To reach this goal, expression of additional eukaryotic glycosyltransferases
is required, and once again, S. cerevisiae is an ideal source for the required en-
zymes. Summarizing, synthesis of N-linked glycans in S. cerevisiae starts on
the cytoplasmic face of the endoplasmic reticulum (ER) where several glyco-
syltransferases (Alg7, Alg13, Alg14, Alg1, Alg2 and Alg11) synthesize a glycan
comprised of 2 N-acetylglucosamine (GlcNAc) residues and 5 mannose (Man)
residues [146]. It is important to address here that this Man5GlcNAc2 struc-
ture is just 2 Man residues away from the trimannose core (Man3GlcNAc2), and
those 2 Man residues are transferred by a single α1,2-mannosyltransferase [122],
Alg11, making it relatively simple to extend the current trimannose synthesis
process for production of Man5GlcNAc2. Figure 3.1 shows the hypothetical
pathway for synthesis of Man5GlcNAc2 in E. coli.
52
Cytoplasm
Periplasm
Inner Membrane
UDP
UDP
GDP
GDP
GDP
WecA Alg13
Alg14
Alg1 Alg2 Alg2
Undecaprenol
N-acetylglucosamine (GlcNAc)
Mannose (Man)
Alg11
GDP
Figure 3.1: Hypothetical pathway for synthesis of Man5GlcNAc2 in E. coli. This picture
shows a schematic for glycan synthesis in E. coli inner membrane. Previ-
ously, expression of Alg13, Alg14, Alg1 and Alg2 from S. cerevisiae in E. coli
permitted the synthesis of Man3GlcNAc2. Now we hypothesize that adding
Alg11 to the system will result on the synthesis of Man5GlcNAc2.
Alg11 is a membrane protein. Previous studies using fusion analysis suggest
that it has an N-terminal transmembrane domain, 2 membrane associated do-
mains and a C-terminal soluble domain [1]. Interestingly, it has been previously
expressed in E. coli as a Thioredoxin C-terminal fusion and proven to be active
in vitro when extracted as part of the membrane fraction [122]. However, no
evidence of in vivo activity in E. coli has been reported before this study.
It is also worth mentioning that terminal α1,2-linked mannose is a recur-
ring feature in some human pathogens [129, 132] and the presence of this struc-
ture on the HIV virus envelope is of particular importance, given several anti-
HIV drugs, currently on testing, bind to terminal α1,2-linked mannose residues
[11, 12, 74, 189]. Taking this into account, the product of Alg11 becomes a par-
ticularly interesting glycan because of its potential use in vaccine research and
development.
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3.2 Materials and methods
3.2.1 Bacterial strains and media
Antibiotic selection was maintained at: 25 µg/mL chloramphenicol (Cam) and
50 µg/mL kanamycin (Kan). Luria Bertani (LB) media was used for E. coli, sup-
plemented with glucose at 0.2% as indicated. Protein expression was induced
by adding L-arabinose and isopropyl -d-thiogalactoside (IPTG) at 0.2% and 100
mM, respectively. Yeast FY834 was maintained on YPD media and synthetic-
defined-Uracil media was used to select or maintain yeast plasmids. E. coli
MC4100 (F- araD139 ∆(argF-lac)U169 flbB5301 deoC1 ptsF25 relA1 rbsR22
rpsL150 thiA) was used as the recipient strain for genetic manipulations. To
delete the gmd gene in MC4100 cells, P1vir phage transduction was performed
using standard methods and the Keio collection [10].
3.2.2 Plasmid construction
Plasmids were constructed using standard homologous recombination in S.
cerevisiae as previously described [149]. Briefly, pMWO7-YCG (see Fig. 1)
was constructed by first PCR amplifying the genes alg13, alg14, alg1, alg2, and
alg11 from S. cerevisiae genomic DNA with primers containing appropriate re-
gions of overlap. The gene encoding for the Mistic protein was PCR ampli-
fied in a similar way from a plasmid template. PCR products and the lin-
earized vector pMWO7 (p15a origin and Cam resistance) were used to trans-
form yeast strain FY834. Constructs assembled in yeast were electroporated into
E. coli for verification via PCR, restriction enzyme digestion and/or sequencing.
pBAD(trxA:alg11:his6)-DEST49 was a generous gift from Dr. Barbara Imperiali.
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Diagrams of the plasmids used in this study are shown in figure 3.2.
alg13
pMWO7-YCG
alg14 alg1 alg2RBSAra RBS RBS RBS
p15a ORI Cat
his6RBSAra
pUC ORI Amp
pBAD(trxA:alg11:his6)-DEST49
alg11trxA
his6RBSAra
pMWO7-mstX:alg11:his6
alg11mstX
p15a ORI Cat
alg13
pMWO7-YCG-alg11
alg14 alg1 alg2RBSAra RBS RBS RBS
p15a ORI Cat
alg11RBS
alg13
pMWO7-YCG-mstX:alg11:his6
alg14 alg1 alg2RBSAra RBS RBS RBS
p15a ORI Cat
his6RBS alg11mstX
Figure 3.2: Plasmids used in this study.
3.2.3 Isolation of membranes and LLOs
Membranes were isolated similarly to the method of Marani et al [106]. For
LLOs extraction, overnight cultures were diluted 1:100 into LB broth and incu-
bated at 37◦C with shaking (250 rpm) until reaching A600 ~0.6. Protein expres-
sion was then induced with 0.2% L-arabinose and cells were incubated at 30◦C
overnight in screw-capped flasks filled with media. Lipid-linked oligosaccha-
rides (LLOs) were extracted and partially purified as described previously [56].
Briefly, the LLO extraction protocolwas based on a total lipid extraction proto-
col using chloroform:water (2:1) as described previously [53]. This solvent mix-
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ture extracts the most hydrophobic lipids, leaving LLOs in the precipitate. The
precipitate was washed with water to remove hydrophilic molecules and then
LLOs were extracted preferentially using chloroform:methanol:water (10:10:3).
Contaminating oligosaccharides not attached to lipids were removed by adsorb-
ing extracted LLOs on DEAE-cellulose. LLOs were then recovered from DEAE-
cellulose using an ammonium acetate solution. After releasing glycans from
LLOs by acid hydrolysis, a butanol/water mixture was used to extract glycans
to the water phase while lipids remained in the butanol phase. Finally, two
ionic exchange resins (AG50W-X8 (Sigma) and AG1-X8 (BioRad)) were used for
removing the remaining salts.
3.2.4 Western blot analysis
Purified protein samples were separated using 12% SDS-PAGE gels and trans-
ferred to PVDF membranes. Proteins that harbored 6x-His affinity tags were
detected with a monoclonal anti-His (C-term) antibody (Invitrogen), per manu-
facturers instructions.
3.2.5 Glycans characterization by mass spectrometry (MS)
Glycans were released from E. coli LLOs as described previously [56]. Some gly-
cans were further digested with C. ensiformis α-exomannosidase in 50 mM am-
monium acetate, pH 4.5, followed by further desalting steps using a carbon col-
umn (envi-carb SPE tube, Supelco). Permethylation of glycans was performed
as described [79]. MALDI-MS profiles were acquired using a 4800 MALDI-
TOF/TOF (Applied Biosystems) in positive ion reflectron mode (500-4000 Da
mass range). MALDI-MS/MS sequencing of permethylated glycans was per-
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formed in positive ion reflectron mode. Air was used as the collision gas. Struc-
ture assignment was according to the method of Yu et al [188].
3.2.6 Fluorophore assisted carbohydrate electrophoresis (FACE)
Glycans were derivatized with 5µL 7amino1,3naphthalenedisulfonic acid
(ANDS) 0.15M in 15% acetic acid and 5µL of 1M sodium cyanoborohydride in
DMSO, and electrophoresed through a 14% acrylamide gel using 0.01% thorin
in 20% glycerol as loading dye, and 1.92M glycine in 0.25M Tris base (pH 8.3)
as running buffer at 10mA constant current [56]. Derivatized glycans were de-
tected as fluorescent bands using a UV transilluminator.
3.3 Results
3.3.1 Expression of Alg11 in E. coli
Expression of Alg11 was attempted using 3 different strategies: from the wild
type sequence (from S. cerevisiae), as a C-terminal fusion to Thioredoxin (TrxA),
and as C-terminal fusion to Mistic (MstX). As reported by O’Reilly et al [122],
when using the wild type sequence for Alg11, western blot analysis shows no
detectable amounts of this protein. However, when expressed as a C-terminal
fusion to TrxA, Alg11 can be detected (83kDa) and it localizes to the membrane
fraction of MC4100 gmd::kan cells (figure 3.3a). In the MstX:Alg11 case, the fu-
sion is also expressed and can be detected in the membrane fraction (77kDa). In
both cases, there seem to be at least 4 lower molecular weight bands presumably
corresponding to degradation products.
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3.3.2 In vivo activity of Alg11
A previous study showed that Man3GlcNAc2 can be synthesized in E.coli given
an appropriate set of glycosyltransferases is expressed in MC4100 gmd::kan
[167]. Based on those results, in vivo activity of Alg11 in E. coli can be assessed
taking advantage of the fact that Man3GlcNAc2 is the natural substrate for Alg11
and that MC4100 gmd::kan accumulates GDP-Man1 in the cytoplasm thanks to
the gmd deletion. In this case, the use of lectins like ConA (from Canavalia ensi-
formis) for glycan analysis is not the best option, taking into account that ConA
reacts in a similar manner with Man3GlcNAc2 and Man5GlcNAc2, so it cannot
be used to discern between these two structures.
Given the above, primary glycan analysis was performed using FACE fol-
lowed by MS for confirmation of results.
Glycan analysis
For evaluation of the in vivo activity of TrxA:Alg11 we used plasmid pMWO7-
YCG for synthesis of the trimannose core and expressed TrxA:Alg11 from plas-
mid pBAD(trxA:alg11:his6)-DEST49. For Alg11 and MstX:Alg11 evaluation,
plasmids pMWO7-YCG-alg11 and pMWO7-YCG-mstX:alg11 were constructed
(figure 3.2), so all glycosyltransferases were expressed from a single plasmid.
Unexpectedly, in opposition to previous experiments in vitro [122],
TrxA:Alg11 did not show any detectable activity in vivo. Given TrxA is a sol-
uble protein, it might be interfering with proper insertion into the membrane,
although TrxA:Alg11 hydrophobic regions could still interact non-specifically
with the membrane, explaining why TrxA:Alg11 shows up in the membrane
fraction.
1This is the sugar-nucleotide donor for Alg11
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On the other hand, wild type Alg11 shows some in vivo activity, neverthe-
less it is not 100% efficient as FACE analysis suggests (figure 3.3b). Further MS
analysis showed that Alg11 efficiency could be around 15% when comparing
the peak corresponding to Hex5HexNAc2 with the Hex3HexNAc2 peak (figure
3.4a), which is in some way an unexpected result given Alg11 expression es-
capes immunoblotting detection. Nevertheless, this would explain why effi-
ciency is still on the low side and, since glycan population is too much hetero-
geneous for some practical purposes, improvement of the system is desirable.
Taking this into account, and in an effort to integrate Alg11 properly to the
membrane, our next step was to try C-terminal fusions to membrane integration
partners such as GlpF and MstX. While GlpF fusion did not express very well
(data not shown), MstX:Alg11 showed good expression and was fully active in
MC4100 gmd::kan (figure 3.3a and b). Surprisingly, in this case the prevalent gly-
coform was Man5GlcNAc2. Furthermore, as MS analysis confirms (figure 3.4b),
all precursors to Man3GlcNAc2 appeared at nearly undetectable amounts, re-
sulting in not just a high MstX:Alg11 efficiency but also a nearly 100% efficiency
for the whole pathway.
Mannosidase analysis
Given the inherent limitations in MS and FACE analysis respect to identifying
linkages between sugar residues, isolated glycans were digested using a α1,2-
mannosidase. As Alg11 attaches 2 mannose residues with specific α1,2 link-
ages, digestion of Man5GlcNAc2 with α1,2-mannosidase should result on pro-
duction of Man3GlcNAc2. FACE analysis of digested and undigested glycans
produced on cells expressing MstX:Alg112 resulted on a banding pattern con-
2This experiment was performed by our colaborators at Glycobia Inc.
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Figure 3.3: Alg11 expression and in vivo activity assessment in E. coli. (a) Expres-
sion of Alg11 fusions in MC4100 gmd::kan. TrxA:Alg11 was expressed
from pBAD(trxA:alg11:his6)-DEST49, while MstX:Alg11 was expressed from
pMWO7-mstX:alg11. (b) FACE analysis of several Alg11 constructs activity
in vivo. TrxA:Alg11 did not show any detectable activity while MstX:Alg11
showed the highest efficiency. (c) α1,2-mannosidase digestion of in vivo
produced glycans after MstX:Alg11 expression. FACE results are consis-
tent with removal of 2 mannose residues from Man5GlcNAc2 to produce
Man3GlcNAc2.
sistent with specific degradation of Man5GlcNAc2 to Man3GlcNAc2, suggesting
that the product of MstX:Alg11 catalytic activity is indeed Man5GlcNAc2 (figure
3.3c).
3.4 Discussion
Alg11 appears not to have any signal peptide compatible with membrane inser-
tion in gram negative bacteria3 , so its insertion into the membrane might not
obey to interactions with the translocation machinery but might be due to hy-
drophobic interactions related to peripheral membrane associated domains that
are not necessarily spanning the membrane. This hypothesis could explain why
3Sequence was analized using SignalP 4.0 server [130]
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Figure 3.4: MS analysis of glycans extracted from E. coli cells expressing glycosyltrans-
ferases for synthesis of Man5GlcNAc2. Analysis of glycans extracted from
MC4100 gmd::kan cells expressing glycosyltransferases for synthesis of
Man3GlcNAc2 and (a) wild type Alg11, or (b) MstX:Alg11. These results
confirm that Alg11 is active in E. coli as well as show that N-terminal MstX
fusion enhance not only Alg11 expression but also the overall pathway per-
formance.
Alg11 manages to attain an active conformation instead of aggregating in the
cytoplasm. Also, since TrxA is a soluble protein and does not have any translo-
cation signal sequence, this Alg11 peripheral membrane associated domains
could be responsible for localization of TrxA:Alg11 to the membrane fraction,
hence interaction with the translocation machinery would not be required.
Surprisingly, TrxA:Alg11 do not show any detectable activity in vivo. Given
previous in vitro experiments based on E. coli expressed TrxA:Alg11 showed the
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expected catalytic activity [122], failure to attach additional mannose residues to
Man3GlcNAc2 in vivo could be a consequence of improper folding or relatively
poor expression. It is possible that during the in vitro experiments an excess of
protein was used, compared to its in vivo availability in E. coli. Additionally, the
in vitro reaction mixture included NP-40 (nonyl phenoxypolyethoxylethanol)
which might play a role on stabilizing the TrxA:Alg11 structure and spatial con-
formation.
It is also worth noticing that Alg11, even though its expression cannot be
detected by immunoblotting, shows catalytic activity in vivo. This suggest that
at least a small fraction of Alg11 reaches a functional configuration, being this
small amount enough to detect activity in MC4100 gmd::kan cells. Neverthe-
less, Man3GlcNAc2 elongation efficiency is relatively low, possibly because of
poor expression of this glycosyltransferase. Given that, as a stabilization and
membrane insertion strategy, N-terminal fusion to MstX was attempted. The
expression profile showed that cellular amounts of MstX:Alg11 were compara-
ble to TrxA:Alg11. Also, membrane localization displayed a similar pattern to
TrxA:Alg11, where MstX:Alg11 was successfully integrated to the membrane.
Fusion to MstX was expected to enhance membrane association and serve as
folding partner to Alg11. From western blot analysis, it is hard to establish any
impact MstX might be having on these two parameters inasmuch as there are
not any evident differences between TrxA:Alg11 and MstX:Alg11 banding pat-
terns. However, from FACE and MS analysis, it becomes evident that MstX fu-
sion is having a positive effect on either Alg11 folding or membrane integration,
or maybe both. Additionally, results indicated that synthesis of Man5GlcNAc2
has a near 100% efficiency with Man3GlcNAc2 and its precursors being at al-
most undetectable levels, suggesting that MstX fusion is not only beneficial for
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Alg11 expression and activity but somehow it is also affecting the performance
of the whole pathway.
Summarizing, the above results showed that fusion to Mstx can enhance
Alg11 expression and activity. Nevertheless, it is difficult to decouple the mem-
brane insertion from the folding enhancement effects given MstX could be im-
pacting both at the esame time. On the other hand, the unexpected lack of
accumulation of Man3GlcNAc2 and its precursors could be hypothetically re-
lated to the native interactions Alg1-Alg2 and Alg1-Alg11 observed in Saccha-
romyces cerevisiae [58]. As a result of these hypothetical interactions, an Alg1-
Alg2-MstX:Alg11 complex could be having a positive kinetic effect, making the
whole glycan synthesis process more efficient. If so, MstX could be responsible
for enhanced membrane insertion, hence facilitating the required interactions
for assembly of this molecular machine.
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CHAPTER 4
FUNCTIONAL EXPRESSION OF GNTI, A HUMAN
GLYCOSYLTRANSFERASE, IN ESCHERICHIA COLI
4.1 Introduction
Recent advances in glycobiology have demonstrated the importance of N-
linked glycosylation for therapeutic proteins [154], being N-glycans structure
and composition of high relevance respect to protein folding and function-
ality, as well as playing a role on targeting this proteins to specific tissues
[15, 154, 163, 151]. With this in mind, industrial scale production of therapeutic
glycoproteins is of high interest but it is also challenge, mostly because synthesis
of glycoproteins suitable for human use is restricted to human cell lines and, in
some cases, to modified mammalian cell lines [45, 126]. In general, while some
of these cell lines show an adequate performance respect to production, there
are several drawbacks inherent to mammalian cells like the need for expensive
media, risk of viral contamination, and relatively difficult genetic manipulation
[38]. Because of that, alternative systems for therapeutic glycoprotein produc-
tion are being investigated.
Some examples of these emerging systems are genetically modified plant
cells, filamentous fungi, insect cells and yeast cells [45]. Nevertheless, an ob-
stacle for the implementation of these alternative systems resides in the diffi-
culty associated with the synthesis of human-like N-glycans that are often nec-
essary to achieve proper functionality and maintain adequate serum half-life
of therapeutic glycoprotein [163]. While most eukaryotic N-glycans, includ-
ing human glycans, share a common core structure known as the trimannose
core (Man3GlcNAc2), their structures diverge widely and most of the time these
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non-human N-glycans result in immunogenicity of their glycoprotein carriers
[126, 135, 162] or poor stability in the blood torrent [15]. Because of this problem,
to produce therapeutic glycoproteins in non-human cells, synthesis of human-
like N-glycans is of critical importance, resulting in a number of studies focused
on this goal using diverse types of eukaryotic organisms [26, 69, 78, 180]. No-
tably, in most of these studies recombinant expression of human glycosyltrans-
ferases has been the strategy of choice.
Given glycosyltransferases are membrane proteins, their recombinant ex-
pression is often difficult [16, 43, 50, 100, 113, 175] and usually they require en-
gineering of the host as well as engineering of the protein itself. Particularly, for
membrane protein engineering, strategies including fusion to folding partners
and membrane integration partners, like MBP and Mistic, have proven to be
very useful [72, 113, 120, 139, 184]. Still, selection of the best engineering strat-
egy is not trivial and often rational design is not enough for ensuring proper
expression, mainly given our limited understanding of protein folding and the
membrane integration process.
Despite those difficulties, recombinant expression of glycosyltransferases
has been achieved in several cases, being of particular relevance for this study
the expression of several glycosyltransferases from S. cerevisiae for synthesis of
the eukaryotic trimannose core in E. coli [167]. In summary, Man3GlcNAc2 was
synthesized by expression of Alg13, Alg14, Alg1 and Alg2 alongside with dele-
tion of the gmd gene from the bacterial host. Interestingly, this development
opened the possibility for synthesizing complex human-like glycans in E. coli
and hence it constitutes a new potential alternative for the production of thera-
peutic glycoproteins at high scale.
Among the most relevant N-glycans required for therapeutic applications
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we find terminally sialylated glycans. In human cells, synthesis of sialylated
biantennary glycans happens in the Golgi apparatus. They are derived from
highly mannosylated glycans which, after being attached to proteins in the en-
doplasmic reticulum, are trimmed down to a Man5GlcNAc2 structure by sev-
eral α-mannosidases [78]. Thereafter, N-acetylglucosaminyltransferase I (GnTI)
transfers a GlcNAc residue on top of this structure [54] and then 2 addi-
tional mannose residues are removed. Finally, a biantennary structure is built
having Man3GlcNAc2 at the core [70]. Interestingly, GnTI can also catalyze
the addition of a GlcNAc unit to Man3GlcNAc2 instead of Man5GlcNAc2, al-
though with a reduced efficiency [54]. Based on this result, the possibility ex-
ists for GlcNAcMan3GlcNAc2 to be synthesized in vivo in E. coli, starting from
Man3GlcNAc2 and then adding a GlcNAc residue by recombinant expression
of GnTI in the cytoplasm. A scheme for this hypothetical pathway in E. coli is
shown in figure 4.1
Cytoplasm
Periplasm
Inner Membrane
UDP
UDP
GDP
GDP
GDP
WecA Alg13
Alg14
Alg1 Alg2 Alg2
Undecaprenol
N-acetylglucosamine (GlcNAc)
Mannose (Man)
GnTI
UDP
Figure 4.1: Hypothetical pathway for synthesis of GlcNAcMan3GlcNAc2 in E. coli. This pic-
ture shows a schematic for glycan synthesis in E. coli inner membrane. Pre-
viously, expression of Alg13, Alg14, Alg1 and Alg2 from S. cerevisiae in E. coli
permitted the synthesis of Man3GlcNAc2. Now we hypothesize that adding
GnTI to the system will result on the synthesis of GlcNAcMan3GlcNAc2.
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Notably, human GnTI has been previously expressed in the cytoplasm of E.
coli as a C-terminal fusion to MBP, and its activity demonstrated in vitro after
purification and immobilization [54]. It is also interesting that 106 amino acids
from the N-terminus can be removed while maintaining catalytic activity. Given
GnTI is a type I membrane protein, these 106 amino acids are probably corre-
sponding to the stem and transmembrane domain, which suggests that GnTI
catalytic site resides in the C-terminal soluble domain [143].
In this study we explored different alternatives for functional expression of
GnTI in E. coli and, for the first time, we were able to demonstrate in vivo activ-
ity of this enzyme by expression of glycosyltransferases from S. cerevisiae and
use of the resulting Man3GlcNAc2 structure as substrate for the synthesis of
GlcNAcMan3GlcNAc2.
4.2 Materials and methods
4.2.1 Bacterial strains and media
Antibiotic selection was maintained at: 25 µg/mL chloramphenicol (Cam) and
50 µg/mL kanamycin (Kan). Luria Bertani (LB) media was used for E. coli, sup-
plemented with glucose at 0.2% as indicated. Protein expression was induced
by adding L-arabinose and isopropyl -d-thiogalactoside (IPTG) at 0.2% and 100
mM, respectively. Yeast FY834 was maintained on YPD media and synthetic-
defined-Uracil media was used to select or maintain yeast plasmids. E. coli
MC4100 (F- araD139 ∆(argF-lac)U169 flbB5301 deoC1 ptsF25 relA1 rbsR22
rpsL150 thiA) was used as the recipient strain for genetic manipulations. To
delete the gmd gene in MC4100 cells, Shuffler T7, Shuffler T7 express, Origamir
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2, and DR473, P1vir phage transduction was performed using standard meth-
ods and the Keio collection [10].
4.2.2 Plasmid construction
Plasmids were constructed using standard homologous recombination in S.
cerevisiae as previously described [149]. Briefly, pMWO7-YCG (see Fig. 1) was
constructed by first PCR amplifying the genes alg13, alg14, alg1, and alg2 from S.
cerevisiae genomic DNA with primers containing appropriate regions of overlap.
The genes encoding for Mistic and GnTI were PCR amplified in a similar way
from a plasmid template (ATCC MGC-2304). PCR products and the linearized
vector pMWO7 (p15a origin and Cam resistance) were used to transform yeast
strain FY834. Constructs assembled in yeast were electroporated into E. coli
for verification via PCR, restriction enzyme digestion and/or sequencing. Dia-
grams of the plasmids used in this study are shown in figure 4.2.
4.2.3 Isolation of membranes and LLOs
Membranes were isolated similarly to the method of Marani et al [106]. For
LLOs extraction, overnight cultures were diluted 1:100 into LB broth and incu-
bated at 37◦C with shaking (250 rpm) until reaching A600 0.6. Protein expres-
sion was then induced with 0.2% L-arabinose and cells were incubated at 30◦C
overnight in screw-capped flasks filled with media. Lipid-linked oligosaccha-
rides (LLOs) were extracted and partially purified as described previously [56].
Briefly, the LLO extraction protocolwas based on a total lipid extraction proto-
col using chloroform:water (2:1) as described previously [53]. This solvent mix-
ture extracts the most hydrophobic lipids, leaving LLOs in the precipitate. The
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alg14 alg1 alg2RBSAra RBS RBS RBS
p15a ORI Cat
his6RBSAra
pMWO7-ΔTMgnTI:his6
ΔTMgnTI
p15a ORI Cat
his6RBSAra
pMWO7-Δssmbp:ΔTMgnTI:his6
ΔTMgnTIΔssmbp
p15a ORI Cat
his6RBSAra
pMWO7-mstX:ΔTMgnTI:his6
ΔTMgnTImstX
p15a ORI Cat
alg13
pMWO7-YCG-mstX:ΔTMgnTI:his6
alg14 alg1 alg2RBSAra RBS RBS RBS
p15a ORI Cat
RBS his6ΔTMgnTImstX
Figure 4.2: Plasmids used in this study.
precipitate was washed with water to remove hydrophilic molecules and then
LLOs were extracted preferentially using chloroform:methanol:water (10:10:3).
Contaminating oligosaccharides not attached to lipids were removed by adsorb-
ing extracted LLOs on DEAE-cellulose. LLOs were then recovered from DEAE-
cellulose using an ammonium acetate solution. After releasing glycans from
LLOs by acid hydrolysis, a butanol/water mixture was used to extract glycans
to the water phase while lipids remained in the butanol phase. Finally, two
ionic exchange resins (AG50W-X8 (Sigma) and AG1-X8 (BioRad)) were used for
removing the remaining salts.
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4.2.4 Western blot analysis
Purified protein samples were separated using 12% SDS-PAGE gels and trans-
ferred to PVDF membranes. Proteins that harbored 6x-His affinity tags were
detected with a monoclonal anti-His (C-term) antibody (Invitrogen), per manu-
facturers instructions.
4.2.5 Glycans characterization by mass spectrometry (MS)
Glycans were released from E. coli LLOs as described previously [56]. Some gly-
cans were further digested with C. ensiformis α-exomannosidase in 50 mM am-
monium acetate, pH 4.5, followed by further desalting steps using a carbon col-
umn (envi-carb SPE tube, Supelco). Permethylation of glycans was performed
as described [79]. MALDI-MS profiles were acquired using a 4800 MALDI-
TOF/TOF (Applied Biosystems) in positive ion reflectron mode (500-4000 Da
mass range). MALDI-MS/MS sequencing of permethylated glycans was per-
formed in positive ion reflectron mode. Air was used as the collision gas. Struc-
ture assignment was according to the method of Yu et al [188].
4.2.6 Fluorophore assisted carbohydrate electrophoresis (FACE)
Glycans were derivatized with 5µL 7amino1,3naphthalenedisulfonic acid
(ANDS) 0.15M in 15% acetic acid and 5µL of 1M sodium cyanoborohydride in
DMSO, and electrophoresed through a 14% acrylamide gel using 0.01% thorin
in 20% glycerol as loading dye, and 1.92M glycine in 0.25M Tris base (pH 8.3)
as running buffer at 10mA constant current [56]. Derivatized glycans were de-
tected as fluorescent bands using a UV transilluminator.
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4.3 Results
4.3.1 Expression of GnTI in E. coli
Three different approaches were evaluated for human GnTI (hGntI) expres-
sion in MC4100 gmd::kan. Since expression of full lenght hGnTI has previ-
ously proven to be difficult [54], probably because of its transmembrane do-
main and the fact that it does not have any signal sequence for membrane
integration in gram negative bacteria1, our starting point was a truncated
hGnTI (∆TMGnTI) lacking the first 106 N-terminal amino acids [143]. Plas-
mid pMWO7-∆TMgnTI:his6 was used for assessing ∆TMGnTI expression. As
shown in figure 4.3a, ∆TMGnTI (43kDa) expression is poor and several degra-
dation bands were detected, suggesting that even without its trasnmembrane
domain and stem ∆TMGnTI is highly unstable in MC4100 gmd::kan.
Following the strategy presented in [54], we proceeded to fuse ∆TMGnTI
to the C-terminus of ∆ssMBP to enhance its solubility and stability. Plasmid
pMWO7-∆ssmbp:∆TMgnTI:his6 was used for expression of ∆ssMBP:∆TMGnTI
(88kDa). This fusion was successfully detected when expressed in MC4100
gmd::kan, although considerable degradation was detected as well (figure 4.3a).
A third approach, contrasting with the ∆ssMBP:∆TMGnTI alternative, was
to fuse ∆TMGnTI to the C-terminus of MstX. In this case, MstX serves not just
as folding partner, but also anchors ∆TMGnTI to the membrane. Given gly-
can synthesis happens on a lipid carrier embedded in the inner membrane, we
hypothesized that MstX:∆TMGnTI attachment to membrane should be kineti-
cally advantageous. As shown in figure 4.3a, when expressing MstX:∆TMGnTI
(56kDa) from pMWO7-mstX:∆TMgnTI:his6, it can be detected in the mem-
1Sequence was analized using SignalP 4.0 server [130]
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Figure 4.3: hGnTI expression and in vivo activity assessment in E. coli. (a) Ex-
pression of hGnTI in MC4100 gmd::kan. ∆TMGnTI was expressed
from pMWO7-∆TMgnTI:his6 and ∆ssMBP:∆TMGnTI was expressed from
pMWO7-∆ssmbp:∆TMgnTI:his6. In both cases, whole cell lysate was
used for immunoblotting. MstX:∆TMGnTI was expressed from pMWO7-
mstX:∆TMgnTI:his6 and the membrane fraction was used for immunoblot-
ting. The evidence suggest that MstX fusion has a stabilizing effect on
hGnTI. (b) FACE analysis of glycans extracted from several E. coli hosts
expressing different hGnTI fusions. c) FACE analysis of glycans extracted
from oxidizing cytoplasm E. coli strains expressing glycosyltransferases for
synthesis of Man3GlcNAc2.
brane fraction. Notably, full lenght MstX:∆TMGnTI appears as the prevalent
band and, while degradation is still present, it is not as extended as in the
∆ssMBP:∆TMGnTI case.
4.3.2 In vivo activity of GnTI
Since ∆TMGnTI is poorly expressed in MC4100 gmd::kan, activity was only as-
sessed for ∆ssMBP:∆TMGnTI and MstX:∆TMGnTI. LLOs were extracted from
1L low oxygen cultures 22h after induction and analyzed using FACE and MS.
FACE analysis (figure 4.3b) indicates that ∆ssMBP:∆TMGnTI is active in
MC4100 gmd::kan, although its efficiency is relatively low when comparing the
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putative GlcNAcMan3GlcNAc2 band intensity to the Man3GlcNAc2 band. In a
similar way, MstX:∆TMGnTI did not show a high efficiency either and it ap-
pears to be even lower than ∆ssMBP:∆TMGnTI, despite the apparent advan-
tage of MstX:∆TMGnTI in regards to expression and lower degradation. MS
analysis confirmed the presence of HexNAcHex3HexNAc2 (peak at 1416 in fig-
ure 4.4) in both ∆ssMBP:∆TMGnTI and MstX:∆TMGnTI samples. However, it
also shows a peak at 1375 corresponding to Man4GlcNAc2, probably a product
from unspecific Alg1 or Alg2 activity [167]. Given this fact, it is also important
to make clear that Man4GlcNAc2 can be detected using FACE, but given the
proximity of the Man4GlcNAc2 to the GlcNAcMan3GlcNAc2 band, FACE anal-
ysis is not sufficient for demonstrating of GlcNAcMan3GlcNAc2 synthesis, so
MS confirmation is always necessary in this particular case.
MS analysis is also useful for estimating the relative efficiency by di-
rect comparison of peak heights. In both cases (figure 4.4a and 4.4b) the
HexNAcMan3HexNAc2 peak is approximately 10% of the Man3GlcNAc2 peak.
Given that, we hypothesized that the poor activity of these enzymes in vivo
could be related to the lack of disulfide bond formation machinery in E. coli
cytoplasm, a reason why oxidizing cytoplasm E. coli strains were considered as
host.
4.3.3 GnTI shows enhanced activity in oxidizing cytoplasm E.
coli
GnTI amino acid sequence includes 5 cysteine residues available for disulfide
bond formation. Even though there is not conclusive evidence regarding disul-
fide bond presence in GnTI structure, previous attempts to produce this enzyme
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Figure 4.4: MS analysis of glycans extracted from E. coli cells expressing glycosyl-
transferases for synthesis of GlcNAcMan3GlcNAc2. (a) Glycans were ex-
tracted from MC4100 gmd::kan carrying pMWO7-YCG-∆ssmbp:∆TMgnTI.
(b) Glycans were extracted from MC4100 gmd::kan carrying pMWO7-YCG-
mstX:∆TMgnTI. In both cases peaks consistent with GnTI enzymatic activity
were found.
in E. coli showed that its solubility and activity benefits from expression in an
oxidizing cytoplasm host [145].
Given the requirement for knocking out the gmd gene to enable MC4100 cells
for synthesis of the trimannose core, we decided to delete this gene from some
oxidizing cytoplasm E. coli strains: Shuffler T7, Origamir 2 and DR473. There-
after, plasmid pMWO7-YCG was used for evaluating production of the triman-
nose core in these modified strains using FACE (figure 4.3c). While trimannose
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core synthesis was detected in all tested oxidizing cytoplasm strains, we limited
GnTI evaluation to Shuffler T7 gmd::kan and Shuffler T7 express gmd::kan. For
this experiment, plasmid pMWO7-YCG-∆ssmbp:∆TMgnTI:his6 was used.
FACE analysis (figure 4.3b) suggests that MstX:∆TMGnTI has little to no
activity in Shuffler T7 gmd::kan. However, its activity in Shuffler T7 ex-
press gmd::kan appears to be better than in MC4100 gmd::kan. When com-
paring the upper band with the Man3GlcNAc2 band we can even infer that
GlcNAcMan3GlcNAc2 production efficiency might be over 50%. Further MS
analysis suggests that MstX:∆TMGnTI is active in Shuffler T7 gmd::kan, de-
spite negative FACE results. Moreover, it appears to have approximately 50%
efficiency (figure 4.5a). On the other hand, its activity in Shuffler T7 express
gmd::kan matches FACE results, confirming that GlcNAcMan3GlcNAc2 produc-
tion efficiency surpasses 50% (figure 4.5b).
4.4 Discussion
As an eukaryotic membrane protein, hGnTI is difficult to express in E. coli given
the lack of bacterial signal sequence for membrane translocation and the ab-
sence of specific eukaryotic chaperones in this host [174]. Fortunately, the mem-
brane associated domain in GnTI is not required for enzymatic activity which
permits engineering of GnTI as a soluble cytoplasmic protein in bacteria. Never-
theless, a version of GntI lacking the first 106 amino acids (∆TMGnTI) failed to
express in MC4100 gmd::kan cytoplasm and instead several bands possibly cor-
responding to degradation products were detected when immunoblotting. To
overcome this problem, two engineering alternatives were tested. First, fusion
to the soluble folding partner MBP (∆ssMBP:∆TMGnTI) for expression of GnTI
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Figure 4.5: MS analysis of glycans extracted from oxidizing cytoplasm E. coli cells ex-
pressing glycosyltransferases for synthesis of GlcNAcMan3GlcNAc2. (a) Gly-
cans were extracted from Shuffler T7 gmd::kan carrying pMWO7-YCG-
∆ssmbp:∆TMgnTI. (b) Glycans were extracted from Shuffler T7 express
gmd::kan carrying pMWO7-YCG-mstX:∆TMgnTI. This analysis suggest that
an oxidizing cytoplasm impacts positively hGnTI catalytic activity, possibly
because it facilitates formation of disulfide bonds.
as a soluble cytoplasmic protein. Second, we rationalized that proper targeting
of GnTI to E. coli inner membrane could be beneficial for reaction kinetics since
glycan synthesis occurs over a lipid carrier embedded in the membrane. Given
that, we decided that MstX (Mistic) had a great potential as folding partner and
membrane anchor. Also, since its C-terminus faces the cytoplasm, we expected
that the fusion protein (MstX:∆TMGnTI) localized the enzymatic hGnTI sub-
unit towards the cytoplasm.
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Both fusion attempts resulted successful respect to protein expression, even
though considerable degradation was detected. Still, MstX:∆TMGnTI seemed
to be a better option given immunoblotting analysis indicated that the full sized
fusion protein was the prevalent band and degradation was not as extended,
while ∆ssMBP:∆TMGnTI appeared less stable. MstX:∆TMGnTI also localized
to the membrane fraction as intended. Furthermore, for the first time, we were
able to show in vivo activity of hGnTI in E. coli even though efficiency was
relatively low, being ∆ssMBP:∆TMGnTI slightly better than MstX:∆TMGnTI.
While this is an interesting result from the scientific point of view, from the en-
gineering perspective there is still space for improvement.
Given some evidence suggesting that hGnTI might have disulfide bonds
in its structure [145] and the fact that it has a number of cysteine residues,
based on previous observations [145], we decided to engineer oxidizing cy-
toplasm strains for production of eukaryotic-like N-glycans. Surprisingly
GlcNAcMan3GlcNAc2 was not detected in Shuffler T7 gmd::kan after FACE
analysis. However, MS analysis suggested that MstX:∆TMGnTI is active in this
strain. On the other hand, Shuffler T7 express gmd::kan produced better results
respect to GlcNAcMan3GlcNAc2 synthesis, possibly because of disulfide bond
formation which may play a role on MstX:∆TMGnTI structure and stability.
Given the quantitative limitations inherent to MS, it is still unclear how much
of this increase in efficiency is effective or is just related to accumulation of the
precursor ManGlcNAc2 (peak at 763 in figure 4.5b) and subsequent reduction
in Man3GlcNAc2 production. Future experiments are planned for glycan quan-
tification and improved comparison of Man3GlcNAc2 related to expression of
MstX:∆TMGnTI. Accumulation of ManGlcNAc2 is also interesting given the
possibility for MstX:∆TMGnTI to be interfering directly with the enzymatic ac-
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tivity of Alg2. It could be speculated that even though MstX:∆TMGnTI cannot
attach a GlcNAc residue to ManGlcNAc2, its affinity towards mannose could
make it compete with Alg2 for this substrate. Additional evidence from our
colaborators at Glycobia inc. might support this asseveration. They evalu-
ated in vivo activity of a N-acetylglucosaminyltransferase from Nicotiana tabacum
(nGnTI), finding that it was active and that ManGlcNAc2 accumulated also in
this case.
In conclusion, human GnTI was successfully expressed in E. coli after modifi-
cations like removal of the N-terminal transmembrane domain and conjugation
to folding and membrane integration partners. Furthermore, in vivo activity was
demonstrated, although efficiency is relatively low. Finally, host engineering
was applied to increase efficiency by use of oxidizing cytoplasm E. coli strains,
facilitating formation of disulfide bonds and possibly stabilizing GnTI structure.
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CHAPTER 5
OPTIMIZING THE SYNTHESIS OF THE TRIMANNOSE CORE IN
ESCHERICHIA COLI
5.1 Introduction
After successful transfer of the N-liked protein glycosylation machinery from
Campylobacter jejuni to E. coli [173], the idea of engineering bacteria for produc-
tion of genuine human glycoproteins is becoming closer to reality. Recently,
our lab in colaboration with Glycobia inc. developed an E. coli based sys-
tem for the synthesis the eukaryotic N-linked glycan common trimannose core
(Man3GlcNAc2) and further transfer of this oligosaccharide to a target glycopro-
tein [167]. The system relies mainly on recombinant expression of several gly-
cosyltransferases from Saccharomyces cerevisiae and an oligosaccharyltransferase
(PglB) from C. jejuni.
The engineering of eukaryotic-like protein glycosylation in E. coli served as
proof of concept for the future development of human-like protein glycosylation
in bacteria. However, alongside with the synthesis of humanized glycans in E.
coli, it is also necessary to assess a number of drawbacks in our current system.
Given glycosyltransferases are membrane proteins, their recombinant ex-
pression is often difficult, being poor expression and toxicity in the bacterial
host the more common problems [16, 43, 50, 100, 113, 175]. Our system is not
the exception, and cell growth rate is severely diminished as a consequence of
the expression of some of the S. cerevisiae glycosyltransferases. On the other
hand PglB, which is also a membrane protein, can affect cell growth as well.
One possible way to overcome the cell growth problem focuses on engineer-
ing of the host. Previously, the pressure exerted by membrane protein overex-
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pression was exploited to isolate spontaneous mutants able to stand to this toxic
effect [111]. A similar approach was successfully applied by our collaborators
at Glycobia inc. for isolation of mutants which growth rate is less affected by
expression of glycosyltransferases.
Interestingly, later studies found that part of the reason why this mutant
hosts were more resistant to membrane protein overexpression was because
they were able to repress expression at the genetic level [176]. Thereafter, this
concept was developed into the restrained expression approach [118], which ra-
tionally represses transcription while enhancing overall expression and mem-
brane integration.
A third approach deals with the amino acid sequence of the protein. Di-
rected evolution of glycosyltransferases has been applied to modify their en-
zymatic activity [166, 183, 182] as well as to enhance natural activity [181]. In
our case, we took advantage of this approach for enhancing enzymatic activity
of selected glycosyltransferases under specific conditions like expression level
and bacterial host. To do so, we took advantage of some interesting features of
the Man3GlcNAc2 synthetic machinery, like display of this glycan on bacterial
surface.
In general, gram negative bacteria synthesize specific glycans known as
O-antigens that are attached to lipid A by WaaL, a relatively promiscuous
ligase [168], resulting in the structure known as lipopolysaccharide. Later,
lipopolysaccharide is transported to the outer membrane by a 7 protein complex
machinery [31, 155] and O-antigens are then displayed on cell surface where
they are available for interaction with external agents. Given the Man3GlcNAc2
synthesis is based partially on the O-antigen synthetic machinery, it is not sur-
prising that WaaL recognizes this structure and therefore Man3GlcNAc2 is incor-
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porated into the lipopolysaccharide and results displayed on the outer surface
of cells. Figure 5.1 presents a schematic of this process.
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Figure 5.1: Synthesis and surface display of Man3GlcNAc2 in E. coli. In this picture a
schematic for glycan synthesis in the inner membrane of E. coli is shown.
Additionally, interaction of this glycan with native lipopolysaccharide syn-
thesis pathway leads to display of the trimannose core on the outer mem-
brane.
This behavior can be exploited to track Man3GlcNAc2 synthesis by labeling
this glycan using concanavalin A (ConA), a lectin extracted from Canavalia ensi-
formis. ConA binds preferentially to mannose residues in the trimannose core,
rendering cells fluorescent when conjugated to a fluorophore like AlexaFluor.
Based on this feature, we hypothesized that improvements in the Man3GlcNAc2
synthetic machinery should be reflected on cells ConA-AlexaFluor fluorescence
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and then this phenotype could be used as a selection tool for sorting libraries of
mutant glycosyltransferases. Here we describe a protocol for generation of suit-
able glycosyltransferase libraries, obtained by error-prone PCR, and selection of
mutants with enhanced properties based on FACS selection.
5.2 Materials and methods
5.2.1 Bacterial strains and media
Antibiotic selection was maintained at: 100 µg/mL ampicillin (Amp), 25 µg/mL
chloramphenicol (Cam) and 50 µg/mL kanamycin (Kan). Luria Bertani (LB)
media was used for E. coli and protein expression was induced by adding L-
arabinose and isopropyl -d-thiogalactoside (IPTG) at 0.2% and 100 mM, re-
spectively. Yeast FY834 was maintained on YPD media and synthetic-defined-
Uracil media was used to select or maintain yeast plasmids. E. coli MC4100 (F-
araD139 ∆(argF-lac)U169 flbB5301 deoC1 ptsF25 relA1 rbsR22 rpsL150 thiA)
was used as the recipient strain for genetic manipulations. To delete the gmd
gene in MC4100 cells, P1vir phage transduction was performed using standard
methods and the Keio collection [10].
5.2.2 Plasmid construction
Plasmids were constructed using standard homologous recombination in S.
cerevisiae as previously described [149]. Briefly, pMWO7-YCG was constructed
by first PCR amplifying the genes alg13, alg14, alg1, and alg2 from S. cerevisiae
genomic DNA with primers containing appropriate regions of overlap. PCR
products and the linearized vector pMWO7 (p15a origin and Cam resistance)
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were used to transform yeast strain FY834. Constructs assembled in yeast were
electroporated into E. coli for verification via PCR, restriction enzyme digestion
and/or sequencing. Plasmids pMWO7-YCG-∆alg14 and pMWO7-YCG-∆alg2
were derived from pMWO7-YCG by restriction enzyme digestion for removal of
either alg14 or alg2 and further re-ligation. Plasmids pTRC99-alg14 and pTRC99-
alg2 were constructed based on pTRC99 using standard techniques. Diagrams
of the plasmids used in this study are shown in figure 5.2. Additionally, for
easier manipulation, plasmids based on pMWO7 were digested and re-ligated
for removal of the genetic information required for working with yeast. This
resulted in a “short” version, ~4000bp smaller than the original.
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Figure 5.2: Plasmids used in this study.
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5.2.3 Construction of alg14 and alg2 libraries
Genes alg14 and alg2 were amplified by error prone PCR using a GeneMorphr
II kit (Agilent Technologies) using primers featuring suitable restriction sites.
Amplified gene libraries were digested and ligated into pTRC99 using standard
techniques. Ligation products were transformed into MC4100 gmd::kan carrying
either pMWO7-YCG-∆alg14 or pMWO7-YCG-∆alg2 and inoculated into 50mL
LB supplemented with Cam, Kan, Amp and using L-arabinose and IPTG as
inducers. Cells were grown at 30◦C under low oxygen conditions for 22h. Flow
cytometry was used for sorting cells.
5.2.4 Flow cytometry
E. coli cells were incubated at 30◦C overnight in LB supplemented with 0.2%
L-arabinose in filled, sealed culture tubes. 1.5mL of the cell suspension was pel-
leted, washed, and resuspended in (PBS). 2.5 µg/mL Canavalia ensiformis Con-
canavalin A (ConA)-AlexaFluor was added to the samples before incubation in
the dark for 30 min at 37◦C with constant agitation. 100 µL of each sample were
analyzed using a FACSCalibur machine (Becton Dickinson). Propidium iodide
was used for labeling dead cells and hence excluding them from the sorting pro-
tocol. Selection of highly fluorescent cells was adjusted at ~20 sorted events per
second from ~1200 total events per second. After sorting, cells were recovered
on a 0.45µm membrane and grown overnight on LB-agar with antibiotics and
glucose. Single colonies were used for further analyses.
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5.2.5 Fluorophore assisted carbohydrate electrophoresis (FACE)
Glycans were derivatized with 5µL 7amino1,3naphthalenedisulfonic acid
(ANDS) 0.15M in 15% acetic acid and 5µL of 1M sodium cyanoborohydride in
DMSO, and electrophoresed through a 14% acrylamide gel using 0.01% thorin
in 20% glycerol as loading dye, and 1.92M glycine in 0.25M Tris base (pH 8.3)
as running buffer at 10mA constant current [56]. Derivatized glycans were de-
tected as fluorescent bands using a UV transilluminator.
5.3 Results
5.3.1 Cells can be sorted based on fluorescent ConA labeling
One important obstacle inherent to our system is the plasmid size. pMWO7-
YCG is 11875 base pairs long, and because of this relatively large size, ligation
of new inserts in to this plasmid is difficult. Also, transformation efficiency into
E. coli competent cells decreases linearly with plasmid size [63], another reason
why use of pMWO7-YCG for library construction may not be very efficient. One
of several possible workarounds to this issue is the use of smaller plasmids for
cloning of error-prone PCR libraries. To do so, we modified pMWO7-YCG by
eliminating either alg14 or alg2, generating pMWO7-YCG-∆alg14 and pMWO7-
YCG-∆alg2. These new plasmids permit the use of a second smaller plasmid for
complementation of the deleted gene (alg14 or alg2) facilitating the construction
of single gene libraries.
This set-up was tested using alg14 as proof of concept. First, plasmid
pMWO7-YCG-∆alg14 was co-transformed with plasmid pTRC99-scFvR4 in
MC4100 gmd::kan cells as negative control (figure 5.3a). The scFvR4 gene was
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selected because it is slightly larger than alg14, facilitating PCR analysis of
mixed populations as well as minimizing the potential bias in this analysis.
Cell growth did not change significantly when replacing alg14 for scFvR4. We
also used pTRC99-alg14 for complementation of the alg14 deletion (figure 5.3b),
which was successfully tested by ConA-AlexaFluor labeling, obtaining the ex-
pected fluorescent phenotype (figure 5.3b).
After showing that alg14 deletion can be complemented from a second plas-
mid, a quick PCR based method for cell population analysis was tested. A single
set of primers specific for the pTRC99 backbone permitted PCR amplification
of either scFvR4 or alg14 from pTRC99-alg14 and pTRC99-scFvR4. When these
plasmids were used for PCR analysis of cell mixtures carrying either pTRC99-
alg14 or pTRC99-scFvR4, a banding pattern consistent with mixture composition
is obtained (figure 5.3c). Using this simple method we were able to determine
what is the prevalent plasmid in any given mixture. Subsequently, we mixed
cells carrying pTRC99-alg14 or pTRC99-scFvR4 in a 5% to 95% ratio. After label-
ing with ConA-AlexaFluor and FACS sorting, 5 random colonies were analyzed
finding that 3 of them were carrying pMWO7-YCG-∆alg14, confirming the tech-
nical feasibility of sorting cell mixtures in favor of the fluorescent phenotype
(figure 5.3d). This experiment served as proof of concept before proceeding to
sort an actual alg14 library.
5.3.2 Alg14 library sorting
MC4100 gmd::kan cells carrying pMWO7-YCG-∆alg14 and an Alg14 library
cloned into pTRC99 were grown overnight under low oxygen conditions for
glycan display. After FACS sorting and cell recovery by membrane filtering,
20 colonies were randomly selected for ConA-AlexaFluor labeling and fluores-
86
alg13
pMWO7-YCG-Δalg14
alg1 alg2RBSAra RBS RBS
p15a ORI Cat
RBSAra
ColE ORI Amp
pTRC99-alg14
alg14
alg13
pMWO7-YCG-Δalg14
alg1 alg2RBSAra RBS RBS
p15a ORI Cat
RBSAra
ColE ORI Amp
pTRC99-scFvR4
scFvR4
100 101 102 103 104
0
250
Ev
en
ts
Fluorescence
100 101 102 103 104
0
250
Ev
en
ts
Fluorescence
scfvR4
alg14
pTRC99-alg14
pTRC99-scFvR4
5% 30% 50% 70% 95%
95% 70% 50% 30% 5%
scfvR4
alg14
a) b)
c) d)
Figure 5.3: ConA-AlexaFluor fluorescence-based cell sorting: proof of concept. (a) Schematics
of the two plasmids system used for testing the feasibility of sorting cells
based ConA-AlexaFluor fluorescence. (b) FACS fluorescence analysis of
MC4100 gmd::kan cells carrying pMWO7-YCG-∆alg14 and pTRC99-scFvR4
or pTRC99-alg14. As expected scFvR4 cannot complement the fluorescent
phenotype while Alg4 expression from pTRC99 successfully complemented
the fluorescent phenotype. (c) Specific primers for the pTRC99 plasmid were
used for PCR-analysis of several mixtures of cells carrying either pTRC99-
scFvR4 or pTRC99-alg14. Band intensity correlated with percentage in the
mixture. (d) PCR-analysis of a mixture of cells carrying 5% pTRC99-alg14
and 95% pTRC99-scFvR4 after FACS sorting and plating on LB-agar with
antibiotics. 5 colonies were randomly selected for PCR-analysis resulting in
3 colonies carrying pTRC99-alg14 (>60%). Based on this result it has been
stated that the system can be efficiently sorted based on fluorescence.
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cence analysis. Cells showing the highest fluorescence were then compared to
cells carrying pMWO7-YCG-∆alg14 and pTRC99-alg14 to confirm that selected
mutants where showing a better performance. Figure 5.4a presents a compari-
son of fluorescence among cells carrying YCG-∆alg14 and the best mutant alg14
gene (pTRC99-alg14mut11), control cells carrying both pMWO7-YCG-∆alg14
and pTRC99-alg14, and a second control population carrying just pMWO7-
YCG. Interestingly, cells carrying pTRC99-alg14mut11, although more fluores-
cent than cells carrying pTRC99-alg14, are not as bright as cells carrying the
single plasmid (pMWO7-YCG).
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Figure 5.4: Analysis of Alg14 mutant 11, isolated from sorted library.. (a) MC4100 gmd::kan
cells carrying pMWO7-YCG or pMWO7-YCG-∆alg14 with pTRC99-alg14
were labeled using ConA-AlexaFluor and compared to cells expressing a
mutated version of Alg14 (Alg14mut11). (b) The impact of Alg14 mutations
on cell growth was analyzed for cells carrying pMWO7-YCG and pMWO7-
YCG-alg14mut11
Because of that difference in fluorescence between controls, alg14mut11 was
cloned back into pMWO7-YCG-∆alg14 to obtain pMWO7-YCG-alg14mut11.
Surprisingly, cells carrying pMWO7-YCG-alg14mut11 were not more fluores-
cent than cells carrying pMWO7-YCG (figure 5.4a). However, when compar-
88
ing for cell growth, cells carrying pMWO7-YCG-alg14mut11 grew consider-
ably faster than cells carrying pMWO7-YCG-alg14 (figure 5.4b), suggesting that
alg14mut11 advantage may be related to reduced toxicity.
5.3.3 Alg2 library sorting
The protocol applied for Alg14 directed evolution was also used for Alg2. In
this case pMWO7-YCG-∆alg2 was complemented using pTRC99-alg2 and the li-
brary was constructed based on this last plasmid. Previously it was shown how
overexpression of Alg14 from pTRC99 affects negatively ConA-AlexaFluor flu-
orescence. On the other hand, we have also observed that overexpression of ei-
ther Alg13 alongside with Alg14 or Alg2 affects negatively cell growth (data not
shown). However, overexpression of Alg2 from pTRC99 does not seem to have
any major impact on ConA-AlexaFluor fluorescence. Furthermore, as show in
figure 5.5, overexpression of a mutant Alg2 (Alg2mutC3) has a positive effect
on ConA-AlexaFluor fluorescence, being it even higher than the single plasmid
control pMWO7-YCG, a somewhat unexpected result given the problems ob-
served with Alg14 overexpression.
For a fair comparison with pMWO7-YCG, alg2mutC3 was cloned back into
pMWO7-YCG-∆alg2 to obtain pMWO7-YCG-alg2mutC3. In this case, ConA-
AlexaFluor fluorescence for pMWO7-YCG-alg2mutC3 resulted slightly inferior
than for pMWO7-YCG (figure 5.5a). This suggest that Alg2mutC3 increased
efficiency may be dependent on overexpression. Nevertheless, overexpression
of Alg2mutC3 appears considerably more deleterious than overexpression of
wild type Alg2 (figure 5.5b). It is also interesting, as shown in figure 5.6a, that
combining the two mutant glycosyltransferases (Alg14mut11 and Alg2mutC3)
in a single plasmid system (pMWO7-YCG-alg14mut11-alg2mutC3) results in to-
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Figure 5.5: Analysis of Alg2 mutant C3, isolated from sorted library.. (a) MC4100 gmd::kan
cells carrying pMWO7-YCG or pMWO7-YCG-∆alg2 with pTRC99-alg2 were
labeled with ConA-AlexaFluor and compared to cells expressing a mutated
version of Alg2 (Alg2mutC3). (b) The impact of Alg2 mutations on cell
growth was analyzed for cells carrying pMWO7-YCG-∆alg2 and pTRC99-
alg2 or pTRC99-alg2mutC3
tal loss of ConA-AlexaFluor fluorescence. Furthermore, when removing one of
the 2 mutations in Alg14mut111, there is a minor recovery of ConA-AlexaFluor
fluorescence. This result is consistent with a hypothetical interaction between
Alg14 and Alg2, but further experimentation is still required.
5.3.4 Analysis of the effect of Alg14 and Alg2 mutations on gly-
can synthesis
Given ConA-AlexaFluor fluorescence analysis is an indirect method for gly-
can analysis that only reflects mannose display on cells surface, glycans were
extracted from MC4100 gmd::kan cells expressing Alg14mut11 or Alg2mutC3.
1Removal of these mutations was achieved using the Quick Change protocol using a “short”
version of pMWO7-YCG-alg14mut11-alg2mutC3 where ~4000bp were removed from the original
plasmid.
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Figure 5.6: Analysis of the impact of Alg14 and Alg2 mutations on glycan synthesis in
MC4100 gmd::kan cells.. (a) ConA-AlexaFluor fluorescence analysis of
cells carrying both Alg14mut11 and Alg2mutC3 where the 2 mutations in
Alg14mut11 have been reverted. Removal of the second mutation results
in partial recovery of the fluorescence phenotype. (b) FACE analysis of gly-
cans extracted from MC4100 gmd::kan cells carrying either Alg14mut11 or
Alg2mutC3. For Alg14mut11 a single plasmid system was used while for
Alg2mutC3 a 2 plasmid system was selected. Samples are normalized re-
spect to O.D.600nm. This experiment shows that there is a proportional
relation between cell fluorescence and glycan production in the inner mem-
brane. (c) MS analyses corresponding to the samples analyzed by FACE.
The analysis suggests that Alg2mutC3 is more efficient than Alg2 wild type
respect to Man3GlcNAc2 synthsis.
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For the Alg14mut11 case, a single plasmid system (pMWO7-YCG-alg14mut11)
was selected given this set-up resulted in higher ConA-AlexaFluor fluorescence.
For the Alg2mutC3 case, a double plasmid system (YCG-∆alg2 with pTRC99-
alg2mutC3) was used because of similar reasons. Glycans were analyzed us-
ing FACE (figure 5.6b) obtaining results that correlate with previous ConA-
AlexaFluor fluorescence analyzes, showing that Man3GlcNAc2 yield is similar
for all cases except for cells carrying YCG-∆alg2 and pTRC99-alg2mutC3, where
Man3GlcNAc2 yield seems to be higher. On the other hand, MS analyzes (figure
5.6c) permitted us to compare Man3GlcNAc2 synthesis respect to Man1GlcNAc2
and Man2GlcNAc2 precursors (results are normalized respect to Man3GlcNAc2)
to establish possible differences between wild type and mutated glycosyltrans-
ferases.
5.4 Discussion
Sorting results suggest that ConA-AlexaFluor fluorescence-based FACS can
select for glycosyltransferases with enhanced properties. Interestingly,
Alg14mut11 does not appear to have an enhanced catalytic activity, but instead
its negative effect over cell growth is less pronounced than that of the wild type
Alg14, suggesting that this mutant may be less toxic. Givent that, it could also
be speculated that low ConA-AlexaFluor fluorescence in the double plasmid
system (YCG-∆alg14 with pTRC99-alg14 or pTRC99-alg14mut11) may be also
related to Alg14 toxicity and hence Alg14 expression should be restrained to
maintain cell viability.
In the Alg2 directed evolution case, the observations are in several ways dif-
ferent. Here, the double plasmid system (YCG-∆alg2 with pTRC99-alg2mutC3)
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resulted in a higher ConA-AlexaFluor fluorescence and even when expressing
the wild type Alg2 (YCG-∆alg2 with pTRC99-alg2) fluorescence is comparable
to pMWO7-YCG. However, when analyzing cell growth, Alg2mutC3 appears to
severely affect the system, completely abolishing growth even 24h after induc-
tion. Nevertheless, the single plasmid system (pMWO7-YCG-alg2mutC3) is only
slightly less fluorescent than pMWO7-YCG, which in some way results counter-
intuitive, considering that Alg2mutC3 appears to be highly toxic for cells, but
its enhanced catalytic activity seems to rely on overexpression.
Respect to our initial hypothesis, an important results is that FACE analysis
from extracted glycans correlates satisfactorily with ConA-AlexaFluor fluores-
cence analysis. When comparing bands corresponding to Man3GlcNAc2 in fig-
ure 5.6b, all samples presented similar band intensity except for cells expressing
Alg2mutC3 (YCG-∆alg2 with pTRC99-alg2mutC3), where band intensity was
higher. Given the extraction protocol favor isolation of LLOs from the inner
membrane, this result serves as evidence for a proportional relation between
LLOs synthesis in the inner membrane and glycan display in the outer mem-
brane after transfer to lipid A by WaaL. This would validate ConA-AlexaFluor
fluorescence as a suitable method for estimation of LLO synthesis efficiency and
glycosyltransferase efficiency, by extension.
On the other hand, MS gives us some clues about the relative activity of
mutant glycosyltransferases. First, Alg14mut11 could be indirectly responsi-
ble for the accumulation of Man1GlcNAc2 (figure 5.6c top) given an increase in
GlcNAc2 production and assuming Alg1 is more efficient than Alg14 and Alg22.
Second, overexpression of Alg2 accounts for depletion of Man1GlcNAc2, favor-
2Overexpression of Alg1 did not show any negative impact on E. coli cells growth. Also,
C-terminal GFP conjugation analysis results in higher fluorescence for Alg1 in comparison to
Alg14 and Alg2 (Data not shown).
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ing Man2GlcNAc2 and Man3GlcNAc2. In the same way Alg2mutC3 would also
deplete Man1GlcNAc2 but this time favoring Man3GlcNAc2 mainly. Unfortu-
nately, Alg2mutC3 toxicity limits its usefulness based on the enzymatic advan-
tage.
In general, the complexity of the system makes hard to predict the directed
evolution outcome. As shown in this study, using similar set-ups, a less toxic
but slightly less efficient glycosyltransferase was obtained and a more toxic but
more efficient glycosyltransferase was also obtained. Additionally, expression
levels of these glycosyltransferases affect dramatically their behavior, where in
the less expected case, activity and toxicity are increased at the same time af-
ter directed evolution. Based on these results, a more robust selection system
should be based on a single plasmid instead of the current 2 plasmid system.
Ideally, the whole operon would be randomly mutated as opposed to single
gene mutagenesis, so glycosyltransferases are co-evolved preventing incompat-
ibilities as observed for pMWO7-YCG-alg14mut11-alg2mutC3 (figure 5.6a).
Given a crystal structure is not available for either Alg14 or Alg2, analysis
of mutations is difficult. Alg14mut11 has two mutations: E49K and Q157H.
According to Alg14 predicted topology [8] the first mutation occurs just after
the N-terminal transmembrane domain, changing from a negatively charged
residue to a positively charged one, which as suggested in previous studies
[14, 98], may affect directionality and membrane insertion and could explain
the decreased toxicity. The second mutation, Q157H, happens on a C-terminal
membrane associated domain. Here, a hydrophobic residue is changed for a
positively charged one, which may be disrupting proper association of this
domain with the membrane. Notably, this disruption is consistent with par-
tial recovery of ConA-AlexaFluor fluorescence after reverting this mutation in
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pMWO7-YCG-alg14mut11-alg2mutC3 and could be involved in the hypothetical
Alg14-Alg2 interaction (figure 5.6a).
On the other hand, 4 mutations were found in Alg2mutC3: A101V, E243K,
T285A and a silent mutation at V166 (GTG to GTC). A101V is located just after
the first predicted transmembrane domain [81], however analysis of this muta-
tion is difficult given both A and V are hydrophobic residues and, according to
codon usage data [119], codons in Alg2 and Alg2mutC3 at this position are both
optimal for E. coli. E243K and T285 may have an important effect on structure
and/or catalytic activity, given these two mutations are located in the main cen-
tral soluble loop where a negatively charged residue is replaced for a positively
charged residue in the first case, and a polar residue is replaced for a hydropho-
bic residue in the second case. Finally, the silent mutation at V166 is located
after the second transmembrane domain, changing from the optimal codon to a
sub-optimal one. Theoretically, this could slow down protein synthesis having
a positive effect on protein folding and membrane insertion.
In summary, ConA-AlexaFluor labeling can be used for directed evolution of
Alg glycosyltransferases in E. coli. Mutant glycosyltransferases with enhanced
activity or decreased toxicity were obtained by this method. Still, results made
evident the importance of co-evolution of this glycosyltransferases to avoid gen-
eral issues derived from non-compatible mutations. Also, expression levels of
this enzymes seems to play an important role on glycan synthesis, a reason why
this variable should be included in future evolution experiments like, for exam-
ple, by mutating ribosome binding sites preceding each gene in the Alg operon.
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CHAPTER 6
CONCLUDING REMARKS AND FUTURE WORK
6.1 Conclusions
Synthesis of the eukaryotic trimannose core glycan was achieved for the first
time in E. coli. This is an important advance not just because this structure
has not been observed or engineered in bacteria before, but because the syn-
thetic pathway requires recombinant expression of four eukaryotic glycosyl-
transferases, three of them membrane proteins. Importantly, the difficulty of
recombinant membrane protein expression in E. coli has been established, and
even when expression is achieved, that does not mean that the protein will be
active in vivo [16, 43, 50, 100, 113, 175], a reason why synthesis of the trimannose
core in this host has been challenging.
Additionally, model proteins were glycosylated in vivo by recombinant ex-
pression of PglB, a bacterial oligosaccharyltransferase from C. jejuni, being this
the first time an eukaryotic-like glycosylation machinery has been engineered in
bacteria. This glycosylation step requires the native E. coli flippases to recognize
the lipid-linked trimannose core to make it available for PglB at the periplasmic
side of the inner membrane. Additionally, since PglB failed to transfer GlcNAc2
from dolichol to a protein in vitro [29], the fact that it can transfer the trimannose
core from bactoprenol to a protein in vivo (even at a low efficiency) constitutes
also an important discovery.
From the engineering point of view, this proof of concept is just the begin-
ning. The engineered glycosylation pathway imposes an important stress on
cells, besides not being efficient enough, making optimization an obligatory
step. Given this factor, directed evolution was applied on two of the glyco-
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syltransferases increasing efficiency in one case and alleviating stress on cells
on the other.
Lastly, the trimannose core while good as a starting point, has limited ap-
plications, so engineering the synthesis of more complex human-like glycans
would open more interesting possibilities. With the synthesis of Man5GlcNAc2
we were able to transfer the whole cytoplasmic N-glycan synthesis pathway
from eukaryotes to E. coli, at the same time that Alg11 activity was demon-
strated for the first time in E. coli. On the other hand, we also were able to
synthesize GlcNAcMan3GlcNAc2 by recombinant expression and engineering
of human GnTI. This result is perhaps more important since hGnTI constitutes
the first step in the synthesis of terminal sialylated glycans, which are of partic-
ular interest given their potential therapeutic applications. Furthermore, hGnTI
activity was shown in E. coli cytoplasm in vivo using an LLO as substrate, which
is notable taking into account that GnTI is a native Golgi enzyme which uses
protein-linked glycans as substrate.
In general, a standardized work flow was established for testing recombi-
nant expression an in vivo activity of glycosyltransferases in E. coli. This ap-
proach permitted the synthesis of the trimannose core and in the future will be
crucial for engineering more complex metabolic pathways leading to the syn-
thesis of fully sialylated and highly mannosylated human-like glycans.
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6.2 Future work
6.2.1 Extension of the trimannose core
While most of the effort will probably be focused on the synthesis of terminal
sialylated glycans, there are additional glycan structures that might also be of
interest. For example, fucosylated glycans are recognized for playing a role on
a number of processes in mammals like cell adhesion and recognition of blood
antigens. They are also involved in some congenital disorders and cancer metas-
tasis [13, 159]. In general, fucose attaches to glycans by α1,2-, α1,3-, α1,4-, and
α1,6- linkages [159], however α1,6-fucose is the main glycoform found in hu-
man N-glycans [112]. Given that, for most practical applications, Fut8 would
be required for production of α1,6-fucosylated glycans [75]. Preliminary Fut81
expression attempts in E. coli have shown relatively good expression levels, al-
though considerable degradation was detected. Importantly, full length Fut8
was also found in the membrane fraction, so since Fut8 is a membrane protein,
there are good chances for it to be properly folded and eventually functional in
vivo (figure 6.1a).
On the other hand, highly mannosylated N-glycans are also interesting
structures, mainly because Man9GlcNAc2 is the prevalent glycan displayed on
HIV capsule protein gp120 [40]. Having Man5GlcNAc2 as starting point, ad-
dition of the sixth mannose residue is catalyzed by Alg3. This step presents
additional challenges when compared to other glycosyltransferases. Alg3 is na-
tively located in the lumen of ER, so instead of GDP-Man it uses dolichol-PP-
Man as substrate [37]. To date, no bacterial enzyme has been identified capable
of attaching mannose directly to bactoprenol, so synthesis of bactoprenol-PP-
1Fut8 from mouse.
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Figure 6.1: Expression of Fut8 and DpmI in E. coli. DpmI can be expressed in E. coli and it
can be found properly localized to the membrane fraction.
Man (as replacement for dolichol-PP-Man in E. coli) would require expression
of another eukaryotic glycosyltransferase. Dolichol-PP-mannosyltransferases
are responsible for the synthesis of dolichol-PP-Man in eukaryotes and usually
happen as complexes made of 2 peptide units. However, after cloning and ex-
pression in E. coli, DpmI was identified as the catalytic subunit in S. cerevisiae
[105]. Furthermore, E. coli expressed DpmI has been shown to transfer mannose
to bactoprenol in vitro [124], which makes it an excellent candidate for attempt-
ing in vivo synthesis of bactoprenol-PP-Man. In our hands, DpmI is expressed
in E. coli and localizes to the membrane fraction, although some degradation
is detected (figure 6.1b). Nevertheless, DpmI functionality in vivo has not been
evaluated yet.
Additionally, Alg3 expression in E. coli has been attempted but we still
have no immunoblotting data available. Instead, based on previous stud-
ies related to membrane protein expression and insertion in the membrane
[50, 99, 110], we tested fusion of Alg3 to the N-terminus of GFP. As positive con-
trol Alg2:GFP was also expressed and fluorescence was evaluated using FACS.
While Alg3:GFP was considerably less fluorescent than Alg2:GFP, two peaks
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were identified in the histograms, suggesting two E. coli populations are present
in the sample where one of them could be carrying fluorescent Alg3:GFP (figure
6.2a). Although, while this does not prove that Alg3 is properly expressed, it at
least suggests that it could be integrated to the membrane with its C-terminus
facing the cytoplasm, as expected from computational topology analysis [123].
Finally, N-terminal fusions to GlpF and Mstx, as membrane integration part-
ners, were attempted in MC4100 (gmd::kan) resulting in MstX working slightly
better. Still, fluorescence is low, possibly because of the relatively large size of
the triple fusion MstX:Alg3:GFP (figure 6.2b).
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Figure 6.2: Fluorescence analysis of C-terminal GFP fusions in E. coli. (a) FACS histograms
of Alg2:GFP and Alg3:GFP expressed in several E. coli strains. (b) Fluores-
cence analysis of GlpF:Alg3:GFP and MstX:Alg3:GFP expression at differ-
ent temperatures. Evidence suggests that Alg3 is poorly expressed in E.coli
while temperature may have a slight positive effect on expression.
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6.2.2 Trimannose core outer membrane display and Outer
Membrane Vesicles (OMVs)
An interesting feature in our system is that the trimannose core synthetic path-
way can interact with the native O-antigen synthetic pathway in E. coli. Waal, a
ligase that transfer the O-antigen from bactoprenol to lipid A, can interact non-
specifically with several glycans [168] including the trimannose core. Because of
that, the trimannose core reaches the outer membrane after conjugation to lipid
A and hence, when synthesized in a hypervesiculating E. coli strain, it would be
displayed on OMVs outer surface.
It has been suggested that mannosylation can enhance lipososme uptake by
macrophages and dendritic cells thanks to interaction with the mannose recep-
tor located in their membrane [32]. As an extension of this observation, we
hypothesize that the trimannose core could have a similar effect on bacterial
OMVs. On the other hand, a recent study showed that OMVs based vaccina-
tion is possible when using antigens located in the luminal space [116], which
could be complementary to the classical outer membrane display approach [28].
This in conjunction with the possibility to move plasmids into OMVs [185][41],
makes it conceivable the engineering of mannosylated OMVs with potential ap-
plication as both protein based and DNA based vaccines. A scheme for the sys-
tem is shown in figure 6.3.
According to Yaron et al. [185], plasmids can get spontaneously into OMVs
by a still unknown mechanism. Furthermore, these OMVs can be used for ge-
netic exchange between bacterial cells. In their study, PCR amplification from
the OMVs preparation is used as the sole proof of DNA being carried by vesi-
cles. Complementary to this approach, we designed an extended experiment to
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Figure 6.3: Mannosylated OMVs as vehicle for delivery of protein and DNA based vaccines.
evaluate if plasmids are effectively inside vesicles instead of being incorporated
to the OMVs preparation by any other mean. Briefly, OMVs carrying a plas-
mid for GFP expression (pTRC-sstorA:gfp) were prepared. This preparation was
treated with DpnI restriction enzyme2 and subsequently DNA was amplified by
PCR. If pTRC-sstorA:gfp is inside vesicles, DpnI should not be able to degrade
it and a PCR product will be detected. As a control, miniprepped pTRC-alg143
was added to the OMVs preparation to confirm DpnI activity. Figure 6.4 shows
the results of this experiment.
For all the PCR reactions, standard primers for pTRC plasmids were use so
any insert can be amplified using the same set of primers. Lane 1 shows re-
sults from PCR amplification directly from OMVs preparation, as described in
Yaron et al. [185], a band corresponding to sstorA:gfp size was detected. For
2DpnI digests methylated bacterial DNA.
3This plasmid was randomly selected only as positive control for DpnI activity
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Figure 6.4: Analysis of plasmid incorporation to the luminal space in OMVs.
the experiment in lane 2, pTRC-alg14 was added to the preparation as well as
buffer 4. Buffer 4 is necessary for DpnI digestion so it was added as control
even in the absence of DpnI. Bands corresponding to sstorA:gfp and alg14 were
expected. However, only an alg14 band was detected. A possible explanation
is that since pTRC-alg14 is outside vesicles, it is more readily accessible to DNA
polymerase, so alg14 amplification overcompetes sstorA:gfp amplification and
this second product is not detected. After DpnI digestion no bands were de-
tected at all (lane 3). The possible reason for this is that DpnI digestion products
from pTRC-alg14 can still anneal to primers so they interfere with sstorA:gfp am-
plification. For this explanation to be valid, the same experiment without addi-
tion of pTRC-alg14 should lead to sstorA::gfp amplification even in the presence
of DpnI, as confirmed in lane 4. Finally, lane 5 shows sstorA:gfp amplification
only in the presence of Buffer 4 and OMVs. Buffer 4 seems to be affecting DNA
polymerase performance, which can be inferred from lane 5 result as well as
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from comparison of lane 1 to all the other lanes. According to this results, we
believe pTRC-sstorA:gfp is being incorporated to the inside of OMVs.
Given our proposed system also requires targeting glycans to OMVs sur-
face, as well as proteins to the lumen, we transformed JC8031 gmd::kan cells
with pMWO7-YCG for synthesis of the trimannose core and pTRC-sstorA:gfp
for synthesis of ssTorA:GFP and targeting to E. coli periplasm (and hence OMVs
lumen) thanks to TorA signal sequence (ssTorA). As shown in figure 6.5a, we
tested OMVs fluorescence to determine GFP presence in the lumen. First we
tested using low oxygen conditions, given MC4100 gmd::kan only display the
trimannose core on its surface under this conditions, however OMVs did not
show any fluorescence. Interestingly, under aerobic conditions, OMVs are flu-
orescent suggesting that functional GFP is present in the lumen. Additionaly.
when probed with ConA-AlexaFluor, OMVs fluorescence increases, probably
because the trimannose core is present on the surface as well.
Protein targeting to OMvs was also assessed by western blot analysis. We
tested targeting of ssTorA:GFP, ssDsbA:HlyA4 and ssTorA:HlyA. Figure 6.5b
shows that in this particular case ssTorA appears to be very efficient at localizing
proteins to OMVs.
Delivery of sstTorA:GFP to mouse macrophages (ATCC J774A.1) in vitro was
also attempted. Results suggest that OMVs were internalized by macrophages
and GFP was hence detected by immunoblotting. Nevertheless, J774A.1 lacks a
mannose receptor, a reason why there is no apparent difference between man-
nosylated and non-mannosylated OMVs (figure 6.5b).
Based on this preliminary data, we consider mannosylated OMVs have po-
tential as a vehicle for delivery of DNA and proteins into macrophages and
4HlyA from Listeria monocytogenes opens pores in the endosome membrane of macrophages
facilitating cell escape or material delivery to the cytoplasm [92, 109].
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Figure 6.5: OMVs glycan display and protein targeting to the lumen. (a) FACS analysis of
OMVs from JC8031 gmd::kan cells expressing ssTorA:GFP and the triman-
nose core. (b) Western blot analysis of proteins targeted to the periplasmic
space for incorporation into OMVs. (c) OMV based delivery of ssTorA:GFP
to mouse macrphages in vitro.
dendritic cells, nevertheless further experimentation is still required.
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APPENDIX A
OPTIMIZED DNA SEQUENCES
A.1 Codon optimized pglBCj
1 ATGCTGAAAA AAGAGTATCT GAAAAACCCT TATCTGGTGC
41 TGTTCGCCAT GATTGTTCTG GCCTATGTGT TTAGCGTGTT
81 CTGCCGCTTC TATTGGGTAT GGTGGGCATC CGAATTCAAC
121 GAGTATTTCT TCAACAACCA GCTGATGATC ATTAGCAATG
161 ACGGCTATGC CTTTGCCGAA GGTGCTCGTG ATATGATTGC
201 CGGCTTTCAC CAACCGAACG ATCTGTCCTA TTACGGTAGC
241 AGCCTGTCTA CACTGACTTA TTGGCTGTAT AAAATCACCC
281 CGTTCTCATT TGAGAGCATT ATCCTGTATA TGTCCACGTT
321 TCTGAGCAGT CTGGTAGTAA TCCCGATTAT TCTGCTGGCC
361 AACGAGTATA AACGCCCGCT GATGGGCTTT GTCGCCGCTC
401 TGCTGGCAAG TGTGGCAAAT TCGTATTATA ACCGTACCAT
441 GTCGGGCTAT TACGATACCG ATATGCTGGT CATCGTACTG
481 CCGATGTTCA TTCTGTTCTT TATGGTCCGT ATGATTCTGA
521 AAAAAGATTT CTTTAGCCTG ATCGCTCTGC CTCTGTTTAT
561 TGGCATCTAT CTGTGGTGGT ATCCGTCGTC GTATACCCTG
601 AATGTTGCCC TGATTGGGCT GTTTCTGATC TATACGCTGA
641 TCTTCCACCG TAAAGAGAAA ATTTTCTATA TCGCCGTGAT
681 CCTGTCTAGT CTGACCCTGA GCAATATTGC CTGGTTCTAT
721 CAGTCAGCCA TCATCGTCAT CCTGTTTGCC CTGTTCGCTC
761 TGGAACAAAA ACGCCTGAAC TTCATGATTA TTGGCATCCT
801 GGGTAGCGCT ACGCTGATCT TCCTGATTCT GTCTGGTGGT
841 GTGGATCCTA TTCTGTATCA ACTGAAATTC TATATTTTCC
106
881 GCTCCGATGA ATCCGCTAAC CTGACACAGG GGTTCATGTA
921 TTTCAACGTC AACCAAACCA TCCAAGAGGT CGAGAATGTC
961 GATTTCTCCG AGTTTATGCG TCGCATTAGT GGCTCTGAGA
1001 TTGTATTCCT GTTCTCACTG TTTGGGTTTG TGTGGCTGCT
1041 GCGTAAACAC AAATCAATGA TTATGGCGCT GCCGATTCTG
1081 GTTCTGGGAT TTCTGGCACT GAAAGGTGGT CTGCGCTTTA
1121 CCATCTATAG CGTTCCGGTA ATGGCACTGG GCTTTGGCTT
1161 TCTGCTGTCC GAGTTCAAAG CAATTCTGGT CAAAAAATAT
1201 TCCCAACTGA CCTCGAATGT GTGTATTGTT TTCGCTACGA
1241 TCCTGACGCT GGCACCTGTT TTTATCCACA TTTATAACTA
1281 TAAAGCACCG ACGGTCTTTT CCCAAAATGA AGCCTCACTG
1321 CTGAATCAAC TGAAAAACAT TGCCAACCGT GAGGACTATG
1361 TGGTAACCTG GTGGGACTAT GGTTATCCGG TTCGCTATTA
1401 TTCCGACGTG AAAACCCTGG TTGATGGTGG TAAACATCTG
1441 GGCAAAGACA ACTTTTTCCC GAGCTTCTCA CTGAGCAAAG
1481 ATGAGCAGGC AGCCGCTAAC ATGGCTCGTC TGAGCGTCGA
1521 GTATACCGAA AAAAGCTTCT ATGCTCCACA AAACGATATC
1561 CTGAAAAGTG ACATCCTGCA GGCCATGATG AAAGACTATA
1601 ACCAGAGCAA CGTCGACCTG TTCCTGGCAT CACTGAGTAA
1641 ACCTGACTTC AAAATCGATA CTCCAAAAAC TCGTGACATT
1681 TATCTGTATA TGCCGGCTCG TATGAGTCTG ATCTTCTCCA
1721 CTGTTGCCTC GTTCTCGTTC ATTAACCTGG ATACGGGTGT
1761 TCTGGACAAA CCGTTCACCT TTTCAACCGC CTATCCGCTG
1801 GACGTGAAAA ATGGCGAGAT CTATCTGAGC AATGGCGTTG
1841 TGCTGTCGGA CGATTTCCGT TCCTTCAAAA TTGGGGACAA
1881 CGTCGTGAGC GTTAACAGTA TTGTCGAGAT TAACAGTATC
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1921 AAACAAGGCG AGTACAAAAT CACTCCTATC GACGATAAAG
1961 CTCAATTCTA TATCTTCTAT CTGAAAGACT CCGCTATTCC
2001 GTATGCTCAA TTCATTCTGA TGGACAAAAC GATGTTCAAC
2041 TCCGCCTATG TCCAAATGTT CTTCCTGGGC AACTATGACA
2081 AAAACCTGTT CGATCTGGTC ATTAACAGTC GTGACGCCAA
2121 AGTGTTCAAA CTGAAAATCT GA
A.2 Codon optimized pglBCl
1 ATGAAACTGC AACAGAACTT TACCGATAAC AACTCCATCA
41 AATATACCTG TATCCTGATC CTGATCGCCT TTGCCTTTAG
81 TGTGCTGTGT CGCCTGTATT GGGTAGCATG GGCATCCGAA
121 TTCTATGAGT TTTTCTTCAA CGACCAGCTG ATGATTACCA
161 CCAACGATGG TTATGCCTTC GCTGAGGGTG CTCGTGATAT
201 GATTGCCGGC TTCCACCAAC CGAATGATCT GTCCTATTTC
241 GGCAGCAGTC TGAGTACACT GACATATTGG CTGTATAGCA
281 TCCTGCCTTT CTCGTTTGAA AGCATTATCC TGTATATGAG
321 CGCCTTCTTT GCTTCTCTGA TTGTTGTCCC GATTATTCTG
361 ATCGCTCGTG AGTATAAACT GACCACCTAT GGCTTCATTG
401 CCGCTCTGCT GGGTTCAATT GCTAACTCGT ATTATAACCG
441 TACCATGTCG GGCTACTATG ACACTGATAT GCTGGTTCTG
481 GTTCTGCCAA TGCTGATTCT GCTGACCTTT ATTCGTCTGA
521 CTATTAACAA AGACATCTTC ACCCTGCTGC TGTCACCGGT
561 TTTTATCATG ATTTATCTGT GGTGGTATCC GTCCTCTTAT
601 AGCCTGAATT TCGCCATGAT CGGGCTGTTT GGTCTGTATA
641 CCCTGGTGTT CCACCGTAAA GAGAAAATCT TCTATCTGAC
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681 GATCGCCCTG ATGATTATTG CCCTGTCTAT GCTGGCCTGG
721 CAGTATAAAC TGGCCCTGAT TGTTCTGCTG TTTGCCATCT
761 TCGCCTTTAA AGAGGAAAAA ATCAACTTCT ATATGATCTG
801 GGCACTGATC TTCATTAGCA TCCTGATCCT GCATCTGTCT
841 GGAGGTCTGG ATCCAGTACT GTATCAACTG AAATTCTATG
881 TGTTCAAAGC CTCCGATGTT CAAAATCTGA AAGACGCCGC
921 CTTCATGTAT TTTAACGTGA ACGAAACCAT TATGGAGGTG
961 AATACCATTG ATCCGGAAGT CTTTATGCAG CGCATTAGTA
1001 GCAGTGTTCT GGTCTTTATC CTGAGCTTCA TCGGGTTCAT
1041 TCTGCTGTGT AAAGATCACA AAAGCATGCT GCTGGCTCTG
1081 CCTATGCTGG CACTGGGTTT TATGGCTCTG CGTGCGGGTC
1121 TGCGTTTTAC CATTTATGCC GTGCCTGTTA TGGCTCTGGG
1161 TTTTGGCTAT TTCCTGTATG CCTTTTTCAA CTTCCTGGAA
1201 AAAAAACAAA TCAAACTGAG CCTGCGCAAC AAAAACATTC
1241 TGCTGATTCT GATTGCCTTC TTTAGCATTT CTCCGGCACT
1281 GATGCACATC TATTATTATA AAAGCTCCAC CGTGTTTACC
1321 AGCTATGAGG CGTCAATTCT GAATGACCTG AAAAACAAAG
1361 CCCAGCGTGA GGATTATGTT GTGGCATGGT GGGACTATGG
1401 ATATCCGATT CGCTATTATT CCGACGTGAA AACCCTGATC
1441 GATGGCGGAA AACATCTGGG TAAAGACAAC TTCTTCAGCA
1481 GCTTTGTGCT GAGTAAAGAA CAAATTCCGG CAGCGAATAT
1521 GGCTCGTCTG AGCGTGGAGT ATACCGAAAA ATCTTTTAAA
1561 GAAAACTATC CGGACGTGCT GAAAGCCATG GTCAAAGACT
1601 ATAACAAAAC CTCGGCGAAA GACTTTCTGG AGTCCCTGAA
1641 CGACAAAGAT TTCAAATTCG ACACCAACAA AACACGTGAC
1681 GTGTATATCT ATATGCCGTA TCGTATGCTG CGTATCATGC
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1721 CTGTAGTAGC CCAATTTGCC AACACGAACC CTGACAATGG
1761 GGAGCAAGAG AAATCGCTGT TCTTCTCACA GGCAAACGCC
1801 ATTGCCCAAG ACAAAACGAC CGGTAGCGTT ATGCTGGATA
1841 ACGGTGTGGA GATTATCAAC GACTTTCGTG CCCTGAAAGT
1881 GGAGGGAGCC TCTATTCCAC TGAAAGCGTT CGTCGACATT
1921 GAGAGTATCA CCAATGGAAA ATTCTATTAT AACGAAATCG
1961 ACTCGAAAGC CCAAATCTAT CTGCTGTTCC TGCGCGAGTA
2001 TAAAAGTTTC GTGATCCTGG ATGAAAGCCT GTATAACAGC
2041 TCGTATATTC AAATGTTCCT GCTGAACCAG TATGACCAGG
2081 ACCTGTTTGA GCAAATCACT AACGACACCC GTGCCAAAAT
2121 CTATCGCCTG AAACGCTGA
A.3 alg14mut11
1 ATGAAAACGG CCTACTTGGC GTCATTGGTG CTCATCGTAT
41 CGACAGCATA TGTTATTAGG TTGATAGCGA TTCTGCCTTT
81 TTTCCACACT CAAGCAGGTA CAGAAAAGGA TACGAAAGAT
121 GGAGTTAACC TACTGAAAAT ACGAGAATCG TCAAAGAAAC
161 CGCTCAAGAT TTTTGTATTC TTAGGATCGG GAGGTCATAC
201 TGGTGAAATG ATCCGTCTTC TAGAAAATTA CCAGGATCTT
241 TTACTGGGTA AGTCGATTGT GTACTTGGGT TATTCTGATG
281 AGGCTTCCAG GCAAAGATTC GCCCACTTTA TAAAAAAATT
321 TGGTCATTGC AAAGTAAAAT ACTATGAATT CATGAAAGCT
361 AGGGAAGTTA AAGCGACTCT CCTACAAAGT GTAAAGACCA
401 TCATTGGAAC GTTGGTACAA TCTTTTGTGC ACGTGGTTAG
441 AATCAGATTT GCTATGTGTG GTTCCCCTCA GCTGTTTTTA
110
481 TTGAATGGGC CTGGAACATG CTGTATAATA TCCTTTTGGT
521 TGAAAATTAT GGAACTTCTT TTGCCCCTGT TGGGTTCCTC
561 CCATATAGTT TATGTAGAAT CGCTGGCAAG GATTAATACT
601 CCTAGTCTGA CCGGAAAAAT ATTATATTGG GTAGTGGATG
641 AATTCATTGT CCAGTGGCAA GAATTGAGGG ACAATTATTT
681 ACCAAGATCC AAGTGGTTCG GCATCCTTGT TTAA
A.4 alg2mutC3
1 ATGATTGAAA AGGATAAAAG AACGATTGCT TTTATTCATC
41 CAGACCTAGG TATTGGGGGC GCTGAAAGGT TAGTCGTCGA
81 TGCAGCATTA GGTCTACAGC AACAAGGACA TAGTGTAATC
121 ATCTATACTA GTCACTGTGA TAAATCACAT TGTTTCGAAG
161 AAGTTAAAAA CGGCCAATTA AAAGTCGAAG TTTATGGTGA
201 TTTTTTACCG ACAAACTTTT TGGGTCGTTT TTTTATTGTT
241 TTCGCAACAA TTAGACAGCT TTATTTAGTT ATTCAATTGA
281 TCCTACAGAA AAAAGTGAAT GTGTACCAAT TAATTATCAT
321 TGATCAACTG TCTACATGTA TTCCGCTTCT GCATATCTTT
361 AGTTCTGCCA CTTTGATGTT TTATTGTCAT TTCCCCGACC
401 AATTATTGGC TCAAAGAGCT GGGCTATTGA AGAAAATATA
441 CAGACTACCA TTTGACTTAA TAGAACAGTT TTCCGTGAGT
481 GCTGCCGATA CTGTTGTCGT AAATTCAAAT TTCACTAAGA
521 ATACGTTCCA CCAAACGTTC AAGTATTTAT CCAATGATCC
561 AGACGTCATT TATCCATGCG TGGATTTATC AACAATCGAA
601 ATTGAAGATA TTGACAAGAA ATTTTTCAAA ACAGTGTTTA
641 ACGAAGGCGA TAGATTTTAC CTAAGTATAA ATCGTTTTGA
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681 GAAAAAAAAG GATGTTGCGC TGGCTATAAA GGCTTTTGCG
721 TTATCTAAAG ATCAAATCAA TGACAACGTT AAGTTAGTTA
761 TTTGCGGTGG TTATGACGAG AGGGTTGCAG AAAATGTGGA
801 GTACTTGAAG GAACTACAGT CTCTGGCCGA TGAATACGAA
841 TTATCCCATA CAGCCATATA CTACCAAGAA ATAAAGCGCG
881 TCTCCGATTT AGAGTCATTC AAAACCAATA ATAGTAAAAT
921 TATATTTTTA ACTTCCATTT CATCATCTCT GAAAGAATTA
961 CTGCTCGAAA GAACCGAAAT GTTATTGTAT ACACCAGCAT
1001 ATGAGCACTT TGGTATTGTT CCTTTAGAAG CCATGAAATT
1041 AGGTAAGCCT GTACTAGCAG TAAACAATGG AGGTCCTTTG
1081 GAGACTATCA AATCTTACGT TGCTGGTGAA AATGAAAGTT
1121 CTGCCACTGG GTGGCTAAAA CCTGCCGTCC CTATTCAATG
1161 GGCTACTGCA ATTGATGAAA GCAGAAAGAT CTTGCAGAAC
1201 GGTTCTGTGA ACTTTGAGAG GAATGGCCCG CTAAGAGTCA
1241 AGAAATACTT TTCTAGGGAA GCAATGACTC AGTCATTTGA
1281 AGAAAACGTC GAGAAAGTCA TATGGAAAGA AAAAAAGTAT
1321 TATCCTTGGG AAATATTCGG TATTTCATTC TCTAATTTTA
1361 TTTTGCATAT GGCATTTATA AAAATTCTAC CCAATAATCC
1401 ATGGCCCTTC CTATTTATGG CCACTTTTAT GGTATTATAT
1441 TTTAAGAACT ACTTATGGGG AATTTACTGG GCATTTGTAT
1481 TCGCTCTCTC CTACCCTTAT GAAGAAATAT AA
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